{"gene":"POU4F1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1993,"finding":"Brn-3a encodes two protein isoforms (long and short); the long form containing an intact N-terminal domain (~100 aa conserved among class IV POU factors) is required for oncogenic transformation of primary fibroblasts, whereas the short form (lacking 84 N-terminal residues) cannot transform. Brn-3b can suppress the oncogenic activity of Brn-3a(l) when co-transfected, acting as an inhibitor.","method":"Focus-formation assay in primary fibroblasts; co-transfection of long vs. short isoforms and Brn-3a/Brn-3b combinations; identification of conserved N-terminal domain by sequence analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transformation assay with isoform constructs and domain mapping, single lab, two orthogonal approaches (focus formation + sequence analysis)","pmids":["8290353"],"is_preprint":false},{"year":1995,"finding":"Brn-3a activates the alpha-internexin promoter via its N-terminal domain, while activation of an artificial promoter containing a synthetic Brn-3a binding site requires only the POU domain. Thus Brn-3a contains two functionally distinct transactivation domains whose activity depends on the target promoter context. Brn-3b represses the alpha-internexin promoter and blocks Brn-3a activation.","method":"Co-transfection reporter assays with chimeric Brn-3a/Brn-3b constructs in neuronal and non-neuronal cells; deletion and domain-swap analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic domain-swap mutagenesis with reporter assays, replicated across multiple construct combinations and cell types","pmids":["7852360"],"is_preprint":false},{"year":1995,"finding":"The short isoform of Brn-3b (Brn-3b(s)) directly interacts with Brn-3a(l) in solution, preventing Brn-3a(l) from forming stable complexes with octamer-related DNA sequences. This heterodimer is transcriptionally inactive and disrupts preformed Brn-3a(l)-DNA complexes, explaining the antagonistic functional relationship between these isoforms.","method":"EMSA (gel mobility shift assay); GST pulldown and in vitro binding studies; co-transfection transcription assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of protein-DNA and protein-protein interactions with multiple orthogonal methods (EMSA, GST pulldown, reporter assays)","pmids":["8537352"],"is_preprint":false},{"year":1996,"finding":"Targeted deletion of Brn-3a causes loss of neurons in the trigeminal ganglia, medial habenula, red nucleus, and inferior olivary nucleus, but not in retina or dorsal root ganglia. In trigeminal and dorsal root ganglia (but not retina), loss of Brn-3a markedly reduces expression of Brn-3b and Brn-3c, indicating that Brn-3a positively regulates these paralogous factors in somatosensory neurons.","method":"Targeted gene deletion in mice; histological analysis; immunohistochemistry; genetic epistasis (Brn-3a KO effect on Brn-3b/3c expression)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype, replicated across multiple neuronal populations, with downstream transcription factor regulation assessed","pmids":["8876243"],"is_preprint":false},{"year":1996,"finding":"The two activation domains of Brn-3a have distinct activities that are dependent on the context of the binding site rather than differences in the target sequence itself. A single-stranded DNA preference for Brn-3a binding was demonstrated for two distinct Brn-3a binding sites.","method":"Co-transfection reporter assays with Brn-3a deletion constructs; EMSA with single- and double-stranded DNA; chimeric promoter analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro DNA binding assays with reporter assays, single lab, two orthogonal methods","pmids":["8621561"],"is_preprint":false},{"year":1997,"finding":"Brn-3a overexpression in undifferentiated ND7 neuronal cells induces neuronal process outgrowth and activates genes encoding synaptic proteins. These effects are primarily dependent on the POU domain (which also serves as an activation domain), and a single amino acid change in the POU homeodomain of Brn-3a to its Brn-3b equivalent abolishes neurite outgrowth induction. Brn-3b does not induce these effects.","method":"Stable overexpression of Brn-3a, Brn-3b, isolated POU domain, and point mutants in ND7 cells; morphological assessment of neurite outgrowth; co-transfection gene expression assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function point mutagenesis, domain deletion, and gain-of-function in neuronal cells with defined morphological readout; multiple orthogonal approaches in one study","pmids":["8972215"],"is_preprint":false},{"year":1997,"finding":"Brn-3a overexpression coordinately upregulates all three neurofilament (NF-L, NF-M, NF-H) gene promoters, whereas Brn-3b has no effect. This activation is mediated by the POU domain, and a single amino acid change in the POU homeodomain converts Brn-3b into an activator of neurofilament promoters.","method":"Co-transfection reporter assays with neurofilament promoters; Western blot and RT-PCR for endogenous protein/mRNA; domain-swap and point mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — promoter activation assays with point mutants, endogenous protein confirmation, multiple neurofilament genes tested; single lab with multiple orthogonal methods","pmids":["9261145"],"is_preprint":false},{"year":1998,"finding":"Brn-3a directly activates the Bcl-2 P2 promoter in neuronal cells through a specific binding site in the promoter; this activation increases Bcl-2 protein levels. The Brn-3a binding site in the P2 promoter is required for maximal activation and for the response during ND7 cell differentiation.","method":"Co-transfection reporter assays; EMSA; Western blot for BCL-2 protein; stable Brn-3a overexpression lines; primary DRG neurons","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct DNA binding (EMSA), endogenous protein upregulation, promoter deletion/mutation, multiple cell types including primary neurons","pmids":["9642226"],"is_preprint":false},{"year":1998,"finding":"Brn-3a and Brn-3b POU domains interact with the DNA-binding domain of the estrogen receptor (ER) independently of ligand. In estradiol-stimulated cells, Brn-3b strongly activates an ERE-containing promoter whereas Brn-3a has a mild inhibitory effect. A single amino acid change in the first helix of the Brn-3a POU homeodomain to the Brn-3b equivalent converts its mild repression to Brn-3b-like activation.","method":"GST pulldown assay; yeast two-hybrid; co-transfection reporter assays with ERE-containing promoter; point mutagenesis of POU homeodomain","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro binding confirmed by two independent methods (pulldown + Y2H), functional consequence tested with mutagenesis, single lab","pmids":["9448000"],"is_preprint":false},{"year":1999,"finding":"Brn-3a strongly activates Bcl-2 promoter activity and this activation is inhibited by p53. p53 requires DNA-binding activity for this inhibitory effect (DNA-binding mutants of p53 do not inhibit). Brn-3a and p53 bind to adjacent sites in the Bcl-2 p2 promoter and directly interact in vitro and in vivo; this interaction is mediated by the POU domain of Brn-3a and the DNA-binding domain of p53. The inhibitory effect is specific to Bcl-2 p1/p2 promoters and not observed on other Brn-3a-activated promoters.","method":"Co-transfection reporter assays; in vitro GST pulldown; co-immunoprecipitation in vivo; EMSA; promoter deletion analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro and in vivo protein-protein interaction confirmed by GST pulldown and co-IP, domain mapping with mutants, promoter specificity tested","pmids":["10329733"],"is_preprint":false},{"year":1999,"finding":"Brn-3a controls survival and differentiation of trigeminal neurons by regulating expression of all three Trk receptors. In Brn-3a-null mice, TrkC-expressing neurons are almost absent from birth, TrkB neurons are transiently elevated then lost, and TrkA expression progressively declines after E12.5, leading to massive apoptosis peaking at E15.5. Surviving neurons predominantly express c-ret and can be sustained by GDNF but not NGF, indicating Brn-3a does not regulate GDNF receptor expression.","method":"Brn-3a knockout mice; immunohistochemistry for Trk receptors; TUNEL apoptosis assay; in vitro neurotrophic factor survival assays on KO neurons; temporal staging","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined molecular targets (three Trk receptors), temporal analysis, functional rescue experiments in culture","pmids":["10357931"],"is_preprint":false},{"year":2001,"finding":"Brn-3a is a transcriptional regulator of soma size, neuronal migration, and axon pathfinding in the inner ear. Absence of Brn-3a causes downregulation of TrkC, parvalbumin, and Brn-3b; selective loss of TrkC-expressing spiral ganglion neurons (phenocopying TrkC-/- mice); and severe retardation of axon projections to the cochlea and posterior vertical canal by E13.5, as well as misrouting of efferent axons.","method":"Brn-3a knockout mouse analysis; immunohistochemistry; DiI axon tracing; temporal staging; comparison with TrkC KO phenotype","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO, multiple downstream targets identified, phenotypic comparison with known pathway component (TrkC KO), axonal tracing","pmids":["11493560"],"is_preprint":false},{"year":2001,"finding":"Brn-3a directly activates the Bcl-xL promoter in sensory but not sympathetic neurons; antisense reduction of Brn-3a reduces Bcl-xL expression; overexpression of Brn-3a in DRG in vivo (sciatic nerve injury model) enhances both Bcl-xL expression and neuronal survival.","method":"Co-transfection reporter assays; antisense oligonucleotides; in vivo Brn-3a overexpression via injection; Western blot; survival counting in DRG","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo overexpression with functional readout, antisense KD, reporter assays; single lab, multiple methods","pmids":["11273642"],"is_preprint":false},{"year":2001,"finding":"Brn-3a minimal promoter in the Bcl-xL locus is activated by Brn-3a and this activation is specifically blocked by p53. The same promoter sequences required for basal activity mediate both Brn-3a activation and p53 repression. A second upstream Bcl-xL promoter is also activated by Brn-3a and repressed by p53.","method":"Co-transfection reporter assays with Bcl-xL promoter deletions; co-expression of Brn-3a and p53","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter functional dissection with deletion analysis, single lab, two promoter regions tested","pmids":["11713302"],"is_preprint":false},{"year":2001,"finding":"Sensory axon growth defects (excessive/premature branching, failure to innervate whisker follicles) precede neuronal death in Brn-3a null mice. These defects resemble those in semaphorin 3A and neuropilin-1 null mice; however, neuropilin-1 expression is maintained in Brn-3a-null sensory neurons, indicating Brn-3a controls axon pathfinding through other downstream genes.","method":"Brn-3a KO crossed to LacZ reporter transgene; whole-mount beta-galactosidase histochemistry for axon visualization; immunohistochemistry for neuropilin-1; temporal analysis of phenotype vs. cell death","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — LacZ-based axon tracing in KO background, temporal dissection of phenotype, molecular marker analysis; single lab with multiple orthogonal approaches","pmids":["11160433"],"is_preprint":false},{"year":2001,"finding":"Overexpression of Brn-3a in cultured trigeminal and DRG sensory neurons enhances survival after NGF withdrawal and activates the endogenous Bcl-2 gene; reducing Brn-3a levels with antisense impairs survival of these neurons. The protective effect is absent in sympathetic neurons. Brn-3b can promote early-stage trigeminal neuron survival but with less temporal breadth than Brn-3a.","method":"Primary neuronal cultures from TG and DRG; overexpression via plasmid transfection; antisense reduction; NGF withdrawal survival assay; Bcl-2 protein measurement","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in primary neurons with survival readout, cell-type specificity demonstrated; single lab","pmids":["11053412"],"is_preprint":false},{"year":2002,"finding":"Brn-3a abolishes p53-mediated activation of the pro-apoptotic Bax promoter and Bax protein expression, while cooperating with p53 to maximally activate the p21(CIP1/Waf1) promoter. At the cellular level, Brn-3a antagonizes p53-induced apoptosis but cooperates with p53 to induce cell cycle arrest.","method":"Co-transfection reporter assays with Bax and p21 promoters; Western blot for Bax and p21 protein; apoptosis and cell cycle assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter + protein level + cellular phenotype; single lab, multiple readouts","pmids":["12203124"],"is_preprint":false},{"year":2003,"finding":"Brn-3a directly binds to specific sites in a 457 bp enhancer that regulates TrkA expression in embryonic sensory neurons. Mutagenesis of these Brn-3a binding sites in the enhancer abolishes appropriate reporter transgene expression in sensory neurons in vivo. Using Bax-KO mice to uncouple cell death from TrkA downregulation confirmed that Brn-3a is required for maintaining TrkA transcriptional activity independently of neurotrophin-dependent survival.","method":"EMSA; transgenic reporter mice with mutagenized enhancer; Bax-KO genetic background epistasis; in vivo transgene expression analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro DNA binding + in vivo enhancer mutagenesis + genetic epistasis with Bax-KO; multiple orthogonal approaches","pmids":["12810599"],"is_preprint":false},{"year":2003,"finding":"Brn-3a negatively autoregulates its own expression by binding to conserved sites within an 11 kb upstream enhancer. In Brn-3a(+/-) mice, expression of the remaining allele is upregulated to near wild-type levels (gene dosage compensation), while transgenic overexpression of Brn-3a suppresses the endogenous gene.","method":"LacZ reporter transgenes; in vivo chromatin-binding analysis; comparison of Brn-3a protein levels in +/+, +/-, and -/- mice; transgenic overexpression","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo evidence from multiple genetic backgrounds, gain-of-function and loss-of-function, site mutagenesis in transgene","pmids":["12441296"],"is_preprint":false},{"year":2003,"finding":"EWS (Ewing's Sarcoma protein) interacts with Brn-3a via the POU domain and the RNA-binding domain of EWS (in vitro), and EWS inhibits Brn-3a-mediated activation of the Bcl-xL promoter.","method":"Yeast two-hybrid screen; in vitro GST pulldown; co-transfection reporter assays","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus GST pulldown (two orthogonal in vitro binding methods) plus reporter assay; single lab","pmids":["12432261"],"is_preprint":false},{"year":2004,"finding":"HIPK2 physically interacts with Brn-3a, promotes Brn-3a DNA binding, but suppresses Brn-3a-dependent transcription of brn3a, trkA, and bcl-xL target genes. HIPK2 overexpression induces apoptosis in sensory neurons, while HIPK2 KO increases Brn-3a, TrkA, and Bcl-xL expression and reduces apoptosis in the trigeminal ganglion.","method":"Co-immunoprecipitation; EMSA; co-transfection reporter assays; HIPK2 overexpression in primary sensory neurons; HIPK2 targeted deletion mouse; immunohistochemistry; TUNEL","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, functional reporter assays, and in vivo KO with defined phenotype; multiple orthogonal methods in one study","pmids":["15492043"],"is_preprint":false},{"year":2004,"finding":"Brn-3a abolishes p53-mediated transcription of the pro-apoptotic gene Noxa. EMSA studies show Brn-3a is associated with p53 when p53 is bound to the Noxa promoter. ChIP confirms Brn-3a association with the wild-type but not mutant Noxa promoter in cells. Co-expression of Brn-3a with p53 reduces endogenous Noxa protein in ND7 neuronal cells. In Brn-3a-/- embryos, both Bax and Noxa proteins are elevated at E14.5, preceding the wave of neuronal apoptosis.","method":"Co-transfection reporter assays; EMSA; ChIP; Western blot for endogenous Noxa and Bax; Brn-3a KO embryo tissue analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP confirms genomic occupancy, EMSA shows protein-DNA association, endogenous protein changes validated, in vivo KO confirmation","pmids":["15598651"],"is_preprint":false},{"year":2004,"finding":"The N-terminal transcriptional activation domain of Brn-3a is essential for neuronal survival in vivo, while the POU domain is essential for neurite outgrowth in vivo. These two functions are thus controlled by separable domains of the protein.","method":"In vivo gene manipulation (domain-specific Brn-3a constructs introduced into mice); neuronal survival quantification; neurite morphology assessment","journal":"Neuroreport","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo domain manipulation, two distinct readouts; single lab","pmids":["15194866"],"is_preprint":false},{"year":2004,"finding":"EWS/Fli-1 (but not EWS alone) interacts with Brn-3a via the C-terminal POU domain. EWS/Fli-1 overexpression specifically inhibits Brn-3a-associated growth arrest and neurite outgrowth and blocks Brn-3a-dependent activation of p21 and SNAP-25 transcription, while EWS more effectively antagonizes the Bcl-2 upregulation function of Brn-3a.","method":"In vitro GST pulldown; co-transfection reporter assays for p21 and SNAP-25; neurite outgrowth and growth arrest assays in neuronal cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro protein interaction plus multiple functional readouts in cells; single lab","pmids":["15021903"],"is_preprint":false},{"year":2003,"finding":"Rin, a neuron-specific small GTP-binding protein, physically interacts with the N-terminal domain of Brn-3a (identified by yeast two-hybrid) and modulates Brn-3a N-terminal-dependent activation of the egr-1 promoter.","method":"Yeast two-hybrid screen; co-transfection reporter assays for egr-1 promoter; N-terminal domain of Brn-3a as bait","journal":"Oncogene","confidence":"Low","confidence_rationale":"Tier 3 / Weak — yeast two-hybrid plus reporter assay, interaction not confirmed by independent method (e.g., co-IP in mammalian cells); single lab","pmids":["12934100"],"is_preprint":false},{"year":2005,"finding":"Brn-3a-expressing RGCs project specifically to the principal retinothalamic/retinocollicular pathway (thalamocortical and collicular visual pathways) and are absent from RGCs serving accessory optic, pretectal, and hypothalamic (circadian) pathways. Brn-3a RGC axons preferentially project to the outer shell of the dorsal lateral geniculate nucleus contralaterally.","method":"Targeted knock-in of tau/beta-galactosidase axonal tracer into the Brn3a locus; anterograde axon tracing; Brn-3a KO analysis of laterality","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic axonal tracing with specific reporter, multiple CNS targets analyzed, KO controls","pmids":["16354917"],"is_preprint":false},{"year":2006,"finding":"Brn-3a is a direct repressor of NeuroD1 and NeuroD4 (pro-neurogenic genes) in embryonic sensory neurons, and also directly modulates its own expression. Locus-wide ChIP in embryonic trigeminal neurons shows that in vivo Brn-3a binding correlates with evolutionary conservation of genomic regions and with active histone modifications (H3 acetylation); not all high-affinity sites are occupied in vivo.","method":"Locus-wide ChIP in embryonic trigeminal neurons; microarray expression profiling of Brn3a-null ganglia; correlation of binding with histone marks and evolutionary conservation","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP in primary embryonic neurons, combined with expression profiling; chromatin state and evolutionary conservation analysis","pmids":["17196582"],"is_preprint":false},{"year":2006,"finding":"Brn-3a and Klf7 synergistically activate the TrkA enhancer in vitro. In double Brn-3a-/-;Klf7-/- mutants, TrkA expression is severely reduced at E12.5 and completely lost by birth (more severe than either single mutant), demonstrating cooperative regulation of endogenous TrkA expression required for nociceptive sensory neuron survival.","method":"Co-transfection reporter assays (synergistic activation); Brn-3a-/-;Klf7-/- double KO mice; in vivo TrkA expression by immunohistochemistry; genetic epistasis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in double KO, in vitro synergy assay, in vivo expression readout; well-controlled study","pmids":["17011544"],"is_preprint":false},{"year":2008,"finding":"The MEK1/2-ERK1/2 signaling pathway regulates Brn-3a N-terminal transcriptional activity during retinoic acid (RA)-mediated neuronal differentiation. Phosphorylation of Brn-3a at serine-122 (and threonine-39) is required for RA-induced neurite outgrowth and N-terminal transactivation of the Galanin promoter. MEK inhibitors block both RA-induced Galanin activation and Brn-3a N-terminal activity; constitutively active MEK1 (but not MEK5) is sufficient to increase Brn-3a activity.","method":"Site-directed mutagenesis of Brn-3a (S122A, T39A); co-transfection reporter assays with Galanin promoter; pharmacological MEK inhibition; constitutively active MEK1/MEK5 expression; neurite outgrowth assay in ND7 cells","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis of phosphorylation sites with functional readout, pathway inhibitors, gain-of-function kinase; single lab","pmids":["19135033"],"is_preprint":false},{"year":2008,"finding":"Brn-3a physically interacts with TAp73 and ΔNp73 isoforms and co-localizes with them in sensory neurons. Brn-3a antagonizes TAp73-mediated transactivation of pro-apoptotic Bax but cooperates with TAp73 to activate p21(CIP1/Waf1). Co-expression with ΔNp73 increases apoptotic protection. The C-terminal region (aa 425-494) of TAp73 is critical for Brn-3a to repress Bax transactivation.","method":"Co-immunoprecipitation; immunofluorescence co-localization; co-transfection reporter assays with Bax and p21 promoters; TAp73 C-terminal deletion constructs","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP in cells, domain mapping, multiple functional readouts; single lab","pmids":["18421303"],"is_preprint":false},{"year":2009,"finding":"Brn-3a-expressing habenular neurons project exclusively to the interpeduncular nucleus. In Brn-3a null embryos, the fasciculus retroflexus forms correctly but habenular neurons fail to innervate their targets. Microarray analysis of Brn-3a null embryos reveals that Brn-3a regulates an extensive program of habenula-enriched genes. The orphan nuclear receptor Nurr1/Nr4a2 is downstream of Brn-3a and mediates expression of a subset of Brn-3a-regulated habenular transcripts.","method":"Brn-3a KO mice; axon tracing; microarray gene expression profiling; genetic epistasis (Nurr1 expression in Brn-3a nulls); bioinformatic analysis","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO with axon tracing, genome-wide expression profiling, genetic epistasis for downstream factor; multiple orthogonal methods","pmids":["19906978"],"is_preprint":false},{"year":2009,"finding":"Brn-3a and Brn-3b control overlapping but distinct aspects of RGC development. Brn-3a deletion alters dendritic stratification and the monostratified:bistratified RGC ratio with little effect on central projections. Brn-3b deletion leads to RGC transdifferentiation and loss, axon defects, and disrupted central projections affecting multiple visually driven behaviors. Both factors are thus required for programming distinct aspects of RGC diversity.","method":"Conditional KO alleles of Brn-3a and Brn-3b with visualization of individual cells; dendritic morphology and stratification analysis; anterograde axon tracing; behavioral testing (visual tasks)","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with single-cell morphology, axon tracing, and behavior; well-controlled dissection of two factors","pmids":["19323995"],"is_preprint":false},{"year":2010,"finding":"Brn-3a acts upstream of Runx transcription factors to specify sensory neuron subtypes in the trigeminal ganglion. In Brn-3a-/- embryos, Runx3 expression is never initiated in TrkC+ neurons and Runx1 expression is severely reduced in TrkA+ neurons. A Brn-3a-VP16 dominant transactivator increases Runx3 mRNA, and Brn-3a binds in vivo by ChIP to a conserved upstream enhancer within H3-acetylated chromatin at the Runx3 locus.","method":"Brn-3a KO mice; Brn-3a-VP16 transgenic mice; ChIP for Brn-3a at Runx3 locus; immunohistochemistry for Trk receptors and Runx factors; histone modification analysis","journal":"Neural development","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP in vivo, gain-of-function (VP16 transactivator) and loss-of-function (KO), histone acetylation context; multiple orthogonal methods","pmids":["20096094"],"is_preprint":false},{"year":2012,"finding":"Brn-3a is required for DRG sensory neuron subtype specification and for central axon projections into the spinal cord. Brn-3a-null DRGs show excessive early generation of TrkB+ and TrkC+ neurons plus double-positive (TrkA+/TrkB+ and TrkA+/TrkC+) cells, followed by loss of TrkB+, TrkC+ and parvalbumin+ neurons and increases in CGRP+ and c-ret+ neurons. TrkA+ afferents fail to enter the dorsal horn and TrkC+ proprioceptive projections to the ventral horn are impaired. Runx1 expression is dramatically downregulated, suggesting Brn-3a acts through Runx1 for specification.","method":"Brn-3a single and Brn-3a;Brn-3b double KO mice; immunohistochemistry for Trk receptors, parvalbumin, CGRP, Runx1; DiI axon tracing; temporal staging","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — double and single KO, multiple molecular markers, axon tracing, temporal analysis; epistasis with Runx1","pmids":["22326227"],"is_preprint":false},{"year":2019,"finding":"Pou4f1 defines a subpopulation of modiolar-side type I spiral ganglion neurons (SGNs). Conditional deletion of Pou4f1 in SGNs after E13 (avoiding early pathfinding/apoptosis phenotypes) alters Ca2+ channel activation in inner hair cells (IHCs), increasing voltage sensitivity and eliminating the normal modiolar-to-pillar gradient of active zone Ca2+ influx strength, without changing SGN numbers, morphology, or synapse distribution.","method":"Conditional KO of Pou4f1 in SGNs (tamoxifen-inducible Cre); immunohistochemistry; Ca2+ imaging of IHC active zones; patch-clamp electrophysiology of IHC Ca2+ channels","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with electrophysiology and Ca2+ imaging readouts, multiple controls to separate developmental from mature function","pmids":["31085606"],"is_preprint":false},{"year":2020,"finding":"Pou4f1 (Brn3a) is a Smad3 target gene and key downstream regulator of macrophage-myofibroblast transition (MMT) in renal fibrosis. ChIP confirmed Pou4f1 as a Smad3 target. Microarray defined a Pou4f1-dependent fibrogenic gene network driving TGF-β1/Smad3-induced MMT. Silencing Pou4f1 in TGF-β1-stimulated bone marrow-derived macrophages, then adoptively transferring them, prevented restoration of MMT and fibrosis in macrophage-depleted mice.","method":"ChIP (Smad3 binding to Pou4f1 locus); microarray gene expression; siRNA silencing; in vitro MMT assay; adoptive transfer of BMDMs into macrophage-depleted mice; two mouse models of renal fibrosis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP, genome-wide expression profiling, in vitro and in vivo functional rescue with KD; multiple orthogonal approaches and two disease models","pmids":["32788346"],"is_preprint":false},{"year":2020,"finding":"POU4F1 promotes BRAF-inhibitor resistance in melanoma by transcriptionally activating MEK expression to re-activate the MAPK/ERK pathway and by increasing MITF expression.","method":"POU4F1 overexpression and knockdown in melanoma cells; Western blot for MEK, ERK, MITF; luciferase reporter assays for MEK promoter; xenograft mouse models","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with reporter assay for MEK promoter and in vivo xenograft; single lab","pmids":["32532957"],"is_preprint":false},{"year":2022,"finding":"HDAC2 represses BRN3A expression in melanocytes and melanoma by maintaining deacetylated chromatin at a distal enhancer of the BRN3A gene. Selective HDAC2 siRNA knockdown increases H3K27ac levels at this BRN3A distal enhancer (confirmed by ChIP-Seq) and upregulates BRN3A expression.","method":"siRNA knockdown of individual HDACs; ChIP-Seq for H3K27ac; pharmacological HDAC inhibitors (class-selective and isoform-selective); RT-PCR and Western blot for BRN3A","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-Seq identifying specific enhancer, isoform-selective siRNA, pharmacological validation; single lab","pmids":["35055045"],"is_preprint":false},{"year":2024,"finding":"ISL1 and POU4F1 directly interact in developing cochleovestibular ganglion (CVG) neurons and cooperate to regulate expression of CVG-specific genes. Compound Isl1;Pou4f1 double KO causes near-complete loss of spiral ganglion neurons—more severe than either single KO—with defects in migration, axon pathfinding, and survival. POU4F1 directly binds cis-regulatory elements of Fgf10, Pou4f2, Epha5 (promoters) and Eya1 and Ntng2 (enhancers).","method":"Isl1 and Pou4f1 single and double KO mice; immunohistochemistry; co-immunoprecipitation of ISL1-POU4F1; ChIP for POU4F1 at target loci; gene expression profiling","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Strong — co-IP demonstrating direct interaction, ChIP at multiple target loci, double KO genetic epistasis with quantitative phenotype; multiple orthogonal methods","pmids":["38267260"],"is_preprint":false},{"year":2024,"finding":"POU4F1 is required for G1/S cell cycle progression in basal-like breast cancer (BLBC) through direct binding at the promoters of CDK2 and CCND1. POU4F1 also maintains BLBC identity by repressing ESR1 (ERα) expression through CDK2-mediated EZH2 phosphorylation and subsequent H3K27me3 modification at the ESR1 promoter. POU4F1 promoter activation in BLBC is maintained by the DNA demethylase TET1, which reconfigures bivalent chromatin to an active state.","method":"POU4F1 KO in BLBC cells; ChIP for POU4F1 at CDK2 and CCND1 promoters; cell cycle and proliferation assays; H3K27me3 ChIP at ESR1; Western blot for ERα and EZH2 phosphorylation; TET1 knockdown and DNA methylation analysis","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP at direct target promoters, KO phenotype, mechanistic pathway (CDK2-EZH2-H3K27me3) validated with multiple orthogonal methods; single lab rigorous study","pmids":["38491910"],"is_preprint":false},{"year":2023,"finding":"Pou4f1 acts as a transcription factor for STAT3, directly regulating STAT3 transcription. In glioma cells, POU4F1 overexpression or STAT3 silencing suppresses XHP-induced pyroptosis, placing Pou4f1 upstream of STAT3 in this pathway.","method":"Dual-luciferase reporter assay for STAT3 promoter; co-IP of POU4F1-STAT3; Western blot; ChIP; siRNA/overexpression in glioma cell lines; in vivo glioma model","journal":"Functional & integrative genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay + ChIP + co-IP confirm direct transcriptional regulation of STAT3; in vivo corroboration; single lab","pmids":["37962640"],"is_preprint":false},{"year":2023,"finding":"Pou4f1 directly binds to the Tbr1 locus (exon 6 and 3'UTR flanking region) and to the Jam2 promoter region; Pou4f1 is required for expression of Tbr1 and Jam2 in J-RGCs. The Pou4f1-bound element in Tbr1 exon 6 has enhancer activity capable of directing reporter expression in J-RGCs, establishing a Pou4f1-Tbr1-Jam2 transcriptional cascade for J-RGC subtype formation.","method":"CUT&RUN (Cleavage Under Targets and Tagmentation); conditional KO of Pou4f1; reporter assay for enhancer activity; immunohistochemistry for Tbr1 and Jam2; in situ hybridization","journal":"Frontiers in ophthalmology","confidence":"High","confidence_rationale":"Tier 1 / Strong — CUT&RUN identifies direct binding sites, KO confirms functional requirement, enhancer reporter validates activity; multiple orthogonal methods","pmids":["38469155"],"is_preprint":false},{"year":2024,"finding":"Runx3 and Brn3a co-bind to numerous genomic loci in early TrkC proprioceptive neurons, primarily at distally located enhancer regions. In activated and suppressed neuronal Runx3 high-confidence target genes, Runx3 cooperates mainly with Brn3a to regulate gene expression through these distant enhancers, while suppression of non-neuronal immune genes is managed by Runx3 without Brn3a.","method":"CUT&RUN for Runx3, Brn3a, Isl1, and H3K27Ac; ATAC-seq; RNA-seq of heterozygous vs. homozygous P2-Runx3 TrkC neurons; bioinformatic co-occupancy analysis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CUT&RUN and ATAC-seq for genomic occupancy, transcriptome for target gene identification; functional validation is indirect (KO of Runx3, not Brn3a); single study","pmids":["39715266"],"is_preprint":false},{"year":2025,"finding":"USP18 stabilizes POU4F1 protein through deubiquitination. POU4F1 in turn promotes transcription of PRKAA2 (AMPK-α2) by binding its promoter (ChIP and dual-luciferase confirmed). USP18-mediated oncogenic effects in lung adenocarcinoma are reversed by POU4F1 knockdown, and POU4F1 regulates cell behaviors via PRKAA2 upregulation.","method":"Immunoprecipitation and ubiquitination assay (USP18-POU4F1 interaction); ChIP and dual-luciferase reporter for POU4F1 at PRKAA2 promoter; siRNA/overexpression; xenograft mouse model","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay + ChIP + reporter for transcriptional regulation, in vivo xenograft; single lab","pmids":["40122823"],"is_preprint":false}],"current_model":"POU4F1/Brn3a is a class IV POU-domain transcription factor that exists as two functionally distinct isoforms (long and short); the long isoform uses an N-terminal transactivation domain to activate anti-apoptotic genes (Bcl-2, Bcl-xL) and protect sensory neurons from apoptosis, while the POU domain drives neurite outgrowth, neurofilament gene expression, and direct DNA binding at target promoters including TrkA, TrkC, Runx3, Tbr1, CDK2, CCND1, and PRKAA2; Brn-3a directly interacts with and differentially modulates the pro-apoptotic transcription factors p53, p73, and HIPK2 (which promotes DNA binding but suppresses transcription), ISL1 (cooperative partner in sensory ganglion development), EWS, and the estrogen receptor; it negatively autoregulates its own expression through upstream enhancer binding; in developing neurons it acts upstream of Runx factors and Nurr1 to specify sensory and habenular neuron subtypes, controls axon pathfinding in trigeminal, spiral, and retinal ganglion cells, and defines functionally distinct RGC subtypes projecting to specific visual targets; in non-neuronal contexts (macrophages, melanoma, leukemia, breast cancer, kidney fibrosis) it regulates fibrogenesis as a Smad3 target, melanoma survival through DNA damage checkpoints, BRAF-inhibitor resistance via MEK transcription, and basal-like breast cancer maintenance through CDK2-EZH2-mediated ERα silencing."},"narrative":{"mechanistic_narrative":"POU4F1 (Brn-3a) is a class IV POU-domain transcription factor that governs survival, differentiation, and subtype identity of sensory and central neurons, and is redeployed in several non-neuronal disease contexts [PMID:8876243, PMID:17196582]. It is expressed as two functionally distinct isoforms: the long form carries an N-terminal transactivation domain required for oncogenic transformation and for neuronal survival in vivo, whereas the POU domain mediates DNA binding, neurite outgrowth, and neurofilament/synaptic gene activation—two separable activities whose output depends on target-promoter context and a single critical residue in the POU homeodomain that distinguishes Brn-3a from its antagonistic paralog Brn-3b [PMID:8290353, PMID:7852360, PMID:8972215, PMID:9261145, PMID:15194866]. The protein binds DNA directly at target promoters and enhancers and supports a pro-survival program by transactivating the anti-apoptotic genes Bcl-2 and Bcl-xL [PMID:9642226, PMID:11273642]. This survival arm is integrated with apoptotic control through direct interaction with the POU domain: Brn-3a binds p53, p73, and HIPK2 to selectively block transactivation of pro-apoptotic targets (Bax, Noxa) while cooperating on the cell-cycle arrest gene p21, and HIPK2 promotes its DNA binding yet suppresses its transcriptional output [PMID:10329733, PMID:12203124, PMID:15492043, PMID:15598651, PMID:18421303]. In sensory neuron development, Brn-3a directly maintains TrkA, TrkB, and TrkC receptor expression—acting at a TrkA enhancer cooperatively with Klf7—and operates upstream of Runx factors and Nurr1 to specify neuronal subtypes while repressing the proneural genes NeuroD1/NeuroD4; its in vivo occupancy correlates with conserved, H3-acetylated chromatin [PMID:10357931, PMID:12810599, PMID:17196582, PMID:17011544, PMID:20096094]. It directs axon pathfinding and target innervation in trigeminal, spiral, habenular, and retinal ganglion neurons, defines functionally distinct RGC subtypes through a Pou4f1-Tbr1-Jam2 cascade, and cooperates with ISL1 to program cochleovestibular ganglion identity [PMID:8876243, PMID:11493560, PMID:16354917, PMID:19906978, PMID:19323995, PMID:38267260, PMID:38469155]. Brn-3a negatively autoregulates its own expression via an upstream enhancer, and its activity is tuned by MEK1/2-ERK phosphorylation at serine-122 [PMID:12441296, PMID:19135033]. In disease settings it serves as a Smad3 target driving macrophage-myofibroblast transition in renal fibrosis, promotes BRAF-inhibitor resistance in melanoma by transactivating MEK, and maintains basal-like breast cancer by activating CDK2/CCND1 and silencing ESR1 through a CDK2-EZH2-H3K27me3 axis [PMID:32788346, PMID:32532957, PMID:38491910].","teleology":[{"year":1995,"claim":"Established that Brn-3a is a bifunctional transcription factor with two separable activation domains whose use is dictated by promoter context, and that the antagonist Brn-3b acts by direct heterodimerization that blocks Brn-3a DNA binding—defining the molecular basis of the Brn-3a/Brn-3b functional opposition.","evidence":"Domain-swap reporter assays plus EMSA and GST pulldown showing Brn-3b(s)–Brn-3a(l) complex formation in vitro","pmids":["7852360","8537352","8290353"],"confidence":"High","gaps":["Endogenous stoichiometry of Brn-3a/Brn-3b heterodimers in neurons not quantified","Structural basis of context-dependent activation-domain choice not resolved"]},{"year":1996,"claim":"Defined the in vivo requirement for Brn-3a in specific neuronal populations and revealed it sits atop a transcription-factor hierarchy by positively regulating its paralogs in somatosensory neurons.","evidence":"Targeted Brn-3a deletion in mice with histology and analysis of Brn-3b/3c expression","pmids":["8876243"],"confidence":"High","gaps":["Direct vs. indirect regulation of Brn-3b/3c not distinguished at this stage","Molecular targets causing neuronal loss not yet identified"]},{"year":1997,"claim":"Mapped neurite outgrowth and neurofilament/synaptic gene activation to the POU domain and pinpointed a single homeodomain residue that confers Brn-3a-specific activity, explaining functional divergence from Brn-3b.","evidence":"Overexpression, domain deletion, and point mutagenesis in ND7 cells with morphological and promoter-reporter readouts","pmids":["8972215","9261145"],"confidence":"High","gaps":["Direct genomic targets mediating outgrowth in vivo not defined","How a single residue alters DNA/cofactor selectivity unknown"]},{"year":1998,"claim":"Identified Bcl-2 as a direct Brn-3a target, linking the transcription factor to a defined anti-apoptotic survival mechanism, and showed POU-domain interaction with the estrogen receptor extends its regulatory reach.","evidence":"EMSA, promoter-reporter assays, Western blot for endogenous BCL-2; GST pulldown and Y2H for ER interaction","pmids":["9642226","9448000"],"confidence":"High","gaps":["In vivo requirement of the Bcl-2 site for neuronal survival not directly tested here","Physiological relevance of ER interaction in neurons unclear"]},{"year":1999,"claim":"Revealed that Brn-3a directly engages p53 to selectively suppress apoptosis while sparing other targets, defining a mechanism by which a neuronal survival factor restrains a pro-apoptotic transcription factor.","evidence":"GST pulldown, co-IP, EMSA, and promoter-deletion reporter assays mapping POU–p53 DNA-binding-domain interaction","pmids":["10329733"],"confidence":"High","gaps":["Structural detail of the Brn-3a–p53 complex on DNA not resolved","Genome-wide scope of selective p53 antagonism not assessed at this stage"]},{"year":2001,"claim":"Extended the survival program to Bcl-xL and demonstrated cell-type specificity (sensory but not sympathetic neurons), establishing Brn-3a as a context-dependent neuroprotective regulator in vivo.","evidence":"Reporter assays, antisense knockdown, in vivo DRG overexpression with survival counts, and Bcl-xL promoter dissection under p53 repression","pmids":["11273642","11713302","11053412"],"confidence":"Medium","gaps":["Mechanistic basis of sensory vs. sympathetic specificity not defined","Single-lab in vivo overexpression data"]},{"year":2001,"claim":"Separated axon-pathfinding defects from neuronal death temporally, establishing that Brn-3a controls trigeminal, spiral, and inner-ear axon guidance through downstream genes other than the semaphorin/neuropilin axis.","evidence":"Brn-3a KO with LacZ axon tracing, DiI tracing, and marker analysis with temporal staging","pmids":["11160433","11493560"],"confidence":"High","gaps":["Direct downstream pathfinding effectors not identified","Mechanism distinguishing guidance from survival functions unresolved"]},{"year":2002,"claim":"Clarified that Brn-3a partitions p53 outputs—blocking apoptosis (Bax/Noxa) while cooperating on cell-cycle arrest (p21)—giving a coherent model for how it shifts cell fate decisions.","evidence":"Promoter-reporter assays, protein-level measurements, and apoptosis/cell-cycle assays; later EMSA/ChIP for Noxa promoter occupancy","pmids":["12203124","15598651"],"confidence":"High","gaps":["How Brn-3a converts p53 from apoptotic to arrest mode at the promoter level not fully resolved","Generality across p53 target promoters not exhaustively mapped"]},{"year":2003,"claim":"Demonstrated direct in vivo enhancer occupancy and uncoupled transcriptional maintenance of TrkA from survival using Bax-KO epistasis, and established negative autoregulation as a dosage-control mechanism.","evidence":"EMSA, transgenic enhancer-mutagenesis reporter mice, Bax-KO epistasis, and autoregulation analysis across Brn-3a genotypes","pmids":["12810599","12441296"],"confidence":"High","gaps":["Cofactors required for enhancer-specific occupancy in vivo not fully defined","Mechanism of autorepression at the chromatin level not resolved"]},{"year":2004,"claim":"Expanded the interaction network to HIPK2, p73, EWS, and EWS/Fli-1, revealing that partners can uncouple DNA binding from transcriptional output and modulate the survival/differentiation balance.","evidence":"Co-IP, EMSA, reporter assays, HIPK2 KO mouse phenotyping, and GST pulldown for EWS/EWS-Fli-1 interactions","pmids":["15492043","18421303","12432261","15021903","15194866"],"confidence":"High","gaps":["Mechanism by which HIPK2 promotes binding yet suppresses transcription not structurally defined","Physiological relevance of EWS/EWS-Fli-1 interactions outside overexpression contexts uncertain"]},{"year":2006,"claim":"Provided a genome-scale view: in vivo Brn-3a occupancy tracks evolutionary conservation and active histone marks, and Brn-3a acts as a direct repressor of proneural genes, refining its role as a context-selective regulator rather than a simple activator.","evidence":"Locus-wide ChIP in embryonic trigeminal neurons combined with expression profiling and chromatin-state correlation","pmids":["17196582"],"confidence":"High","gaps":["Determinants of in vivo site selection beyond conservation/histone state not defined","Repressor mechanism at NeuroD loci not mechanistically dissected"]},{"year":2010,"claim":"Placed Brn-3a in a transcriptional hierarchy upstream of Runx factors and Nurr1, establishing it as a master regulator of sensory and habenular neuron subtype specification through direct enhancer binding.","evidence":"KO and VP16-transactivator mice, in vivo ChIP at the Runx3 locus, axon tracing, and microarray epistasis for Nurr1","pmids":["20096094","19906978","17011544"],"confidence":"High","gaps":["Combinatorial logic with Runx/Nurr1 not fully resolved","Direct vs. indirect targets within subtype programs not all distinguished"]},{"year":2012,"claim":"Demonstrated that Brn-3a is required for DRG subtype diversification and central afferent projections, with Runx1 as a downstream specification mediator, extending the developmental program to the spinal sensory system.","evidence":"Single and Brn-3a;Brn-3b double KO mice with marker analysis, DiI tracing, and temporal staging","pmids":["22326227"],"confidence":"High","gaps":["Direct Runx1 regulation in DRG not shown by ChIP here","Effectors of central axon entry not identified"]},{"year":2019,"claim":"Distinguished a mature, post-developmental function: Pou4f1 tunes inner-hair-cell Ca2+ channel properties and the modiolar–pillar activity gradient in spiral ganglion neurons independent of its earlier survival/pathfinding roles.","evidence":"Tamoxifen-inducible conditional KO after E13 with Ca2+ imaging and patch-clamp electrophysiology","pmids":["31085606"],"confidence":"High","gaps":["Transcriptional targets mediating the Ca2+ phenotype not identified","Cell-autonomous vs. retrograde signaling basis unclear"]},{"year":2024,"claim":"Defined RGC and cochleovestibular subtype programs at the level of direct binding, including a Pou4f1-Tbr1-Jam2 cascade and ISL1 cooperativity, sharpening the model of combinatorial subtype specification.","evidence":"CUT&RUN/ChIP for direct targets, conditional and double KO genetic epistasis, co-IP of ISL1-POU4F1, and enhancer reporter assays","pmids":["38469155","38267260","39715266"],"confidence":"High","gaps":["Full target catalog of each cooperative partnership incomplete","Brn3a-specific functional validation in the Runx3 co-occupancy study is indirect"]},{"year":2025,"claim":"Established disease-context roles in which POU4F1 is itself regulated (Smad3 transactivation, HDAC2/TET1 chromatin control, USP18 deubiquitination) and drives fibrogenic, drug-resistance, oncogenic-proliferation, and identity programs through direct target promoters.","evidence":"ChIP/CUT&RUN at MEK, CDK2/CCND1, ESR1, STAT3, PRKAA2 loci; KO/knockdown with in vitro and xenograft/adoptive-transfer functional readouts","pmids":["32788346","32532957","35055045","38491910","37962640","40122823"],"confidence":"High","gaps":["Whether neuronal-survival mechanisms operate identically in tumor cells not established","Cross-talk among the multiple disease pathways not integrated"]},{"year":null,"claim":"How POU4F1 selects among activation, repression, and apoptosis-modulating modes at individual loci—and how a single homeodomain residue and partner identity dictate output—remains mechanistically unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of Brn-3a–DNA–cofactor complexes","Determinants of in vivo site selection beyond conservation and histone state undefined","Unifying logic linking developmental and disease target programs unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,5,6,7,26,32,39,41]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,4,7,17,21,26,32,41]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[9,21,26]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,7,26,32]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,10,30,31,33,38]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[9,16,20,21,29]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[16,39]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[35,36,39,40,43]}],"complexes":[],"partners":["POU4F2","TP53","TP73","HIPK2","ISL1","ESR1","EWSR1","RUNX3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q01851","full_name":"POU domain, class 4, transcription factor 1","aliases":["Brain-specific homeobox/POU domain protein 3A","Brain-3A","Brn-3A","Homeobox/POU domain protein RDC-1","Oct-T1"],"length_aa":419,"mass_kda":42.7,"function":"Multifunctional transcription factor with different regions mediating its different effects. Acts by binding (via its C-terminal domain) to sequences related to the consensus octamer motif 5'-ATGCAAAT-3' in the regulatory regions of its target genes. Regulates the expression of specific genes involved in differentiation and survival within a subset of neuronal lineages. It has been shown that activation of some of these genes requires its N-terminal domain, maybe through a neuronal-specific cofactor. Activates BCL2 expression and protects neuronal cells from apoptosis (via the N-terminal domain). Induces neuronal process outgrowth and the coordinate expression of genes encoding synaptic proteins. Exerts its major developmental effects in somatosensory neurons and in brainstem nuclei involved in motor control. Stimulates the binding affinity of the nuclear estrogene receptor ESR1 to DNA estrogen response element (ERE), and hence modulates ESR1-induced transcriptional activity. May positively regulate POU4F2 and POU4F3. Regulates dorsal root ganglion sensory neuron specification and axonal projection into the spinal cord. Plays a role in TNFSF11-mediated terminal osteoclast differentiation. Negatively regulates its own expression interacting directly with a highly conserved autoregulatory domain surrounding the transcription initiation site Able to act as transcription factor, cannot regulate the expression of the same subset of genes than isoform 1. Does not have antiapoptotic effect on neuronal cells","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q01851/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/POU4F1","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/POU4F1","total_profiled":1310},"omim":[{"mim_id":"619830","title":"DEVELOPING BRAIN HOMEOBOX 1; DBX1","url":"https://www.omim.org/entry/619830"},{"mim_id":"619352","title":"ATAXIA, INTENTION TREMOR, AND HYPOTONIA SYNDROME, CHILDHOOD-ONSET; ATITHS","url":"https://www.omim.org/entry/619352"},{"mim_id":"609592","title":"RIC-LIKE PROTEIN WITHOUT CAAX MOTIF 2; RIT2","url":"https://www.omim.org/entry/609592"},{"mim_id":"603196","title":"COCHLIN; COCH","url":"https://www.omim.org/entry/603196"},{"mim_id":"602083","title":"USHER SYNDROME, TYPE IF; USH1F","url":"https://www.omim.org/entry/602083"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in single","driving_tissues":[{"tissue":"retina","ntpm":2.4}],"url":"https://www.proteinatlas.org/search/POU4F1"},"hgnc":{"alias_symbol":["RDC-1"],"prev_symbol":["BRN3A"]},"alphafold":{"accession":"Q01851","domains":[{"cath_id":"1.10.260.40","chopping":"243-346","consensus_level":"high","plddt":81.5609,"start":243,"end":346},{"cath_id":"1.10.10.60","chopping":"365-415","consensus_level":"high","plddt":92.6655,"start":365,"end":415}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01851","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q01851-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q01851-F1-predicted_aligned_error_v6.png","plddt_mean":60.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=POU4F1","jax_strain_url":"https://www.jax.org/strain/search?query=POU4F1"},"sequence":{"accession":"Q01851","fasta_url":"https://rest.uniprot.org/uniprotkb/Q01851.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q01851/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q01851"}},"corpus_meta":[{"pmid":"19264888","id":"PMC_19264888","title":"Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19264888","citation_count":489,"is_preprint":false},{"pmid":"19323995","id":"PMC_19323995","title":"Distinct roles of transcription factors brn3a and brn3b in controlling the development, morphology, and function of retinal ganglion cells.","date":"2009","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/19323995","citation_count":220,"is_preprint":false},{"pmid":"8876243","id":"PMC_8876243","title":"Targeted deletion of the mouse POU domain gene Brn-3a causes selective loss of neurons in the brainstem and trigeminal ganglion, uncoordinated limb movement, and impaired suckling.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8876243","citation_count":201,"is_preprint":false},{"pmid":"16354917","id":"PMC_16354917","title":"Brn3a-expressing retinal ganglion cells project specifically to thalamocortical and collicular visual pathways.","date":"2005","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16354917","citation_count":145,"is_preprint":false},{"pmid":"32788346","id":"PMC_32788346","title":"Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage-myofibroblast transition.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32788346","citation_count":139,"is_preprint":false},{"pmid":"10329733","id":"PMC_10329733","title":"p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10329733","citation_count":130,"is_preprint":false},{"pmid":"11493560","id":"PMC_11493560","title":"Brn3a is a transcriptional regulator of soma size, target field innervation and axon pathfinding of inner ear sensory neurons.","date":"2001","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/11493560","citation_count":123,"is_preprint":false},{"pmid":"10357931","id":"PMC_10357931","title":"POU domain factor Brn-3a controls the differentiation and survival of trigeminal neurons by regulating Trk receptor expression.","date":"1999","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10357931","citation_count":107,"is_preprint":false},{"pmid":"9642226","id":"PMC_9642226","title":"Bcl-2 transcription from the proximal P2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9642226","citation_count":106,"is_preprint":false},{"pmid":"19906978","id":"PMC_19906978","title":"Brn3a and Nurr1 mediate a gene regulatory pathway for habenula development.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19906978","citation_count":101,"is_preprint":false},{"pmid":"11160433","id":"PMC_11160433","title":"Defects in sensory axon growth precede neuronal death in Brn3a-deficient mice.","date":"2001","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11160433","citation_count":87,"is_preprint":false},{"pmid":"15492043","id":"PMC_15492043","title":"Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival.","date":"2004","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15492043","citation_count":85,"is_preprint":false},{"pmid":"8290353","id":"PMC_8290353","title":"Mouse Brn-3 family of POU transcription factors: a new aminoterminal domain is crucial for the oncogenic activity of Brn-3a.","date":"1993","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8290353","citation_count":84,"is_preprint":false},{"pmid":"20826176","id":"PMC_20826176","title":"Morphologies of mouse retinal ganglion cells expressing transcription factors Brn3a, Brn3b, and Brn3c: analysis of wild type and mutant cells using genetically-directed sparse labeling.","date":"2010","source":"Vision research","url":"https://pubmed.ncbi.nlm.nih.gov/20826176","citation_count":79,"is_preprint":false},{"pmid":"21315070","id":"PMC_21315070","title":"Brain derived neurotrophic factor maintains Brn3a expression in axotomized rat retinal ganglion cells.","date":"2011","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/21315070","citation_count":76,"is_preprint":false},{"pmid":"7852360","id":"PMC_7852360","title":"Activation of the alpha-internexin promoter by the Brn-3a transcription factor is dependent on the N-terminal region of the protein.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7852360","citation_count":67,"is_preprint":false},{"pmid":"15598651","id":"PMC_15598651","title":"Brn-3a transcription factor blocks p53-mediated activation of proapoptotic target genes Noxa and Bax in vitro and in vivo to determine cell fate.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15598651","citation_count":60,"is_preprint":false},{"pmid":"8972215","id":"PMC_8972215","title":"The Brn-3a transcription factor induces neuronal process outgrowth and the coordinate expression of genes encoding synaptic proteins.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8972215","citation_count":59,"is_preprint":false},{"pmid":"22326227","id":"PMC_22326227","title":"Brn3a/Pou4f1 regulates dorsal root ganglion sensory neuron specification and axonal projection into the spinal cord.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22326227","citation_count":58,"is_preprint":false},{"pmid":"12810599","id":"PMC_12810599","title":"Brn3a regulation of TrkA/NGF receptor expression in developing sensory neurons.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12810599","citation_count":56,"is_preprint":false},{"pmid":"12441296","id":"PMC_12441296","title":"Direct autoregulation and gene dosage compensation by POU-domain transcription factor Brn3a.","date":"2003","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12441296","citation_count":55,"is_preprint":false},{"pmid":"11713302","id":"PMC_11713302","title":"A minimal Bcl-x promoter is activated by Brn-3a and repressed by p53.","date":"2001","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/11713302","citation_count":55,"is_preprint":false},{"pmid":"9448000","id":"PMC_9448000","title":"POU transcription factors Brn-3a and Brn-3b interact with the estrogen receptor and differentially regulate transcriptional activity via an estrogen response element.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9448000","citation_count":54,"is_preprint":false},{"pmid":"10980200","id":"PMC_10980200","title":"Coordinated Up-regulation by hypoxia of adrenomedullin and one of its putative receptors (RDC-1) in cells of the rat blood-brain barrier.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10980200","citation_count":52,"is_preprint":false},{"pmid":"9261145","id":"PMC_9261145","title":"Coordinate induction of the three neurofilament genes by the Brn-3a transcription factor.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9261145","citation_count":50,"is_preprint":false},{"pmid":"11053412","id":"PMC_11053412","title":"The BRN-3A transcription factor protects sensory but not sympathetic neurons from programmed cell death/apoptosis.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11053412","citation_count":49,"is_preprint":false},{"pmid":"12203124","id":"PMC_12203124","title":"The Brn-3a transcription factor inhibits the pro-apoptotic effect of p53 and enhances cell cycle arrest by differentially regulating the activity of the p53 target genes encoding Bax and p21(CIP1/Waf1).","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12203124","citation_count":48,"is_preprint":false},{"pmid":"31085606","id":"PMC_31085606","title":"Pou4f1 Defines a Subgroup of Type I Spiral Ganglion Neurons and Is Necessary for Normal Inner Hair Cell Presynaptic Ca2+ Signaling.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31085606","citation_count":46,"is_preprint":false},{"pmid":"11273642","id":"PMC_11273642","title":"Brn-3a activates the expression of Bcl-x(L) and promotes neuronal survival in vivo as well as in vitro.","date":"2001","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/11273642","citation_count":46,"is_preprint":false},{"pmid":"20096094","id":"PMC_20096094","title":"Brn3a regulates neuronal subtype specification in the trigeminal ganglion by promoting Runx expression during sensory differentiation.","date":"2010","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/20096094","citation_count":43,"is_preprint":false},{"pmid":"15968082","id":"PMC_15968082","title":"Axotomy-induced early down-regulation of POU-IV class transcription factors Brn-3a and Brn-3b in retinal ganglion cells.","date":"2005","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/15968082","citation_count":35,"is_preprint":false},{"pmid":"17011544","id":"PMC_17011544","title":"Brn3a and Klf7 cooperate to control TrkA expression in sensory neurons.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17011544","citation_count":34,"is_preprint":false},{"pmid":"24709358","id":"PMC_24709358","title":"Comparative expression analysis of POU4F1, POU4F2 and ISL1 in developing mouse cochleovestibular ganglion neurons.","date":"2014","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/24709358","citation_count":33,"is_preprint":false},{"pmid":"9541499","id":"PMC_9541499","title":"The HPV-activating cellular transcription factor Brn-3a is overexpressed in CIN3 cervical lesions.","date":"1998","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9541499","citation_count":33,"is_preprint":false},{"pmid":"9839440","id":"PMC_9839440","title":"The Brn-3a transcription factor.","date":"1998","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9839440","citation_count":32,"is_preprint":false},{"pmid":"17196582","id":"PMC_17196582","title":"Brn3a target gene recognition in embryonic sensory neurons.","date":"2006","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/17196582","citation_count":31,"is_preprint":false},{"pmid":"11470235","id":"PMC_11470235","title":"The closely related POU family transcription factors Brn-3a and Brn-3b are expressed in distinct cell types in the testis.","date":"2001","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11470235","citation_count":30,"is_preprint":false},{"pmid":"7797498","id":"PMC_7797498","title":"The neuronal nicotinic acetylcholine receptor alpha 2 subunit gene promoter is activated by the Brn-3b POU family transcription factor and not by Brn-3a or Brn-3c.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7797498","citation_count":29,"is_preprint":false},{"pmid":"8835784","id":"PMC_8835784","title":"Alternative splicing of the Brn-3a and Brn-3b transcription factor RNAs is regulated in neuronal cells.","date":"1996","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/8835784","citation_count":28,"is_preprint":false},{"pmid":"23666755","id":"PMC_23666755","title":"The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival.","date":"2013","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23666755","citation_count":27,"is_preprint":false},{"pmid":"32532957","id":"PMC_32532957","title":"POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32532957","citation_count":25,"is_preprint":false},{"pmid":"8989239","id":"PMC_8989239","title":"High expression of the POU factor Brn3a in aggressive neuroendocrine tumors.","date":"1997","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8989239","citation_count":24,"is_preprint":false},{"pmid":"15021903","id":"PMC_15021903","title":"The effects of Brn-3a on neuronal differentiation and apoptosis are differentially modulated by EWS and its oncogenic derivative EWS/Fli-1.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15021903","citation_count":24,"is_preprint":false},{"pmid":"24736625","id":"PMC_24736625","title":"Pou4f1 and pou4f2 are dispensable for the long-term survival of adult retinal ganglion cells in mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24736625","citation_count":22,"is_preprint":false},{"pmid":"20376082","id":"PMC_20376082","title":"POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/20376082","citation_count":22,"is_preprint":false},{"pmid":"12150774","id":"PMC_12150774","title":"Effect of Brn-3a deficiency on parvalbumin-, calbindin D-28k-, calretinin- and calcitonin gene-related peptide-immunoreactive primary sensory neurons in the trigeminal ganglion.","date":"2002","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12150774","citation_count":22,"is_preprint":false},{"pmid":"11521202","id":"PMC_11521202","title":"The Brn-3a transcription factor plays a key role in regulating the growth of cervical cancer cells in vivo.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11521202","citation_count":21,"is_preprint":false},{"pmid":"16276351","id":"PMC_16276351","title":"Brn-3a neuronal transcription factor functional expression in human prostate cancer.","date":"2006","source":"Prostate cancer and prostatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16276351","citation_count":21,"is_preprint":false},{"pmid":"15126036","id":"PMC_15126036","title":"Effect of Brn-3a deficiency on parvalbumin-immunoreactive primary sensory neurons in the dorsal root ganglion.","date":"2004","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15126036","citation_count":18,"is_preprint":false},{"pmid":"29958540","id":"PMC_29958540","title":"Postnatal developmental dynamics of cell type specification genes in Brn3a/Pou4f1 Retinal Ganglion Cells.","date":"2018","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/29958540","citation_count":16,"is_preprint":false},{"pmid":"32988584","id":"PMC_32988584","title":"POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32988584","citation_count":16,"is_preprint":false},{"pmid":"9582431","id":"PMC_9582431","title":"NT-3 regulates expression of Brn3a but not Brn3b in developing mouse trigeminal sensory neurons.","date":"1998","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/9582431","citation_count":16,"is_preprint":false},{"pmid":"8537352","id":"PMC_8537352","title":"Short isoform of POU factor Brn-3b can form a heterodimer with Brn-3a that is inactive for octamer motif binding.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8537352","citation_count":16,"is_preprint":false},{"pmid":"7731552","id":"PMC_7731552","title":"The levels of the antagonistic POU family transcription factors Brn-3a and Brn-3b in neuronal cells are regulated in opposite directions by serum growth factors.","date":"1995","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/7731552","citation_count":16,"is_preprint":false},{"pmid":"32821525","id":"PMC_32821525","title":"Software for Quantifying and Batch Processing Images of Brn3a and RBPMS Immunolabelled Retinal Ganglion Cells in Retinal Wholemounts.","date":"2020","source":"Translational vision science & technology","url":"https://pubmed.ncbi.nlm.nih.gov/32821525","citation_count":15,"is_preprint":false},{"pmid":"16384672","id":"PMC_16384672","title":"Effects of Brn-3a protein and RNA expression in rat brain following low-level lead exposure during development on spatial learning and memory.","date":"2005","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/16384672","citation_count":15,"is_preprint":false},{"pmid":"8903036","id":"PMC_8903036","title":"Similarities and differences among inner retinal neurons revealed by the expression of reporter transgenes controlled by Brn-3a, Brn-3b, and Brn-3c promotor sequences.","date":"1996","source":"Visual neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8903036","citation_count":15,"is_preprint":false},{"pmid":"15532030","id":"PMC_15532030","title":"Coexpression of Brn-3a POU protein with p53 in a population of neuronal progenitor cells is associated with differentiation and protection against apoptosis.","date":"2004","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/15532030","citation_count":15,"is_preprint":false},{"pmid":"38491910","id":"PMC_38491910","title":"Activation of Bivalent Gene POU4F1 Promotes and Maintains Basal-like Breast Cancer.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38491910","citation_count":14,"is_preprint":false},{"pmid":"20460523","id":"PMC_20460523","title":"AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20460523","citation_count":14,"is_preprint":false},{"pmid":"27391320","id":"PMC_27391320","title":"Brn3a and Brn3b knockout mice display unvaried retinal fine structure despite major morphological and numerical alterations of ganglion cells.","date":"2016","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27391320","citation_count":14,"is_preprint":false},{"pmid":"8621561","id":"PMC_8621561","title":"The different activities of the two activation domains of the Brn-3a transcription factor are dependent on the context of the binding site.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8621561","citation_count":14,"is_preprint":false},{"pmid":"8782654","id":"PMC_8782654","title":"The functionally antagonistic POU family transcription factors Brn-3a and Brn-3b show opposite changes in expression during the growth arrest and differentiation of human neuroblastoma cells.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8782654","citation_count":13,"is_preprint":false},{"pmid":"28594399","id":"PMC_28594399","title":"Essential but partially redundant roles for POU4F1/Brn-3a and POU4F2/Brn-3b transcription factors in the developing heart.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28594399","citation_count":12,"is_preprint":false},{"pmid":"19135033","id":"PMC_19135033","title":"Regulation of Brn-3a N-terminal transcriptional activity by MEK1/2-ERK1/2 signalling in neural differentiation.","date":"2008","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/19135033","citation_count":12,"is_preprint":false},{"pmid":"12225879","id":"PMC_12225879","title":"Effect of Brn-3a deficiency on nociceptors and low-threshold mechanoreceptors in the trigeminal ganglion.","date":"2002","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/12225879","citation_count":12,"is_preprint":false},{"pmid":"12893201","id":"PMC_12893201","title":"Measurement of Brn-3a levels in Pap smears provides a novel diagnostic marker for the detection of cervical neoplasia.","date":"2003","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12893201","citation_count":12,"is_preprint":false},{"pmid":"16247485","id":"PMC_16247485","title":"Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16247485","citation_count":11,"is_preprint":false},{"pmid":"25698939","id":"PMC_25698939","title":"Red nucleus and rubrospinal tract disorganization in the absence of Pou4f1.","date":"2015","source":"Frontiers in neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/25698939","citation_count":10,"is_preprint":false},{"pmid":"12405260","id":"PMC_12405260","title":"Brn-3a, a neuronal transcription factor of the POU gene family: indications for its involvement in cancer and angiogenesis.","date":"2002","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12405260","citation_count":10,"is_preprint":false},{"pmid":"15725417","id":"PMC_15725417","title":"Brn-3a deficiency increases tyrosine hydroxylase-immunoreactive neurons in the dorsal root ganglion.","date":"2005","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15725417","citation_count":10,"is_preprint":false},{"pmid":"12432261","id":"PMC_12432261","title":"The pro-oncoprotein EWS (Ewing's Sarcoma protein) interacts with the Brn-3a POU transcription factor and inhibits its ability to activate transcription.","date":"2002","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/12432261","citation_count":10,"is_preprint":false},{"pmid":"38587440","id":"PMC_38587440","title":"Comparison of Brn3a and RBPMS Labeling to Assess Retinal Ganglion Cell Loss During Aging and in a Model of Optic Neuropathy.","date":"2024","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/38587440","citation_count":9,"is_preprint":false},{"pmid":"11711852","id":"PMC_11711852","title":"The POU domain transcription factor Brn-3a protects cortical neurons from apoptosis.","date":"2001","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11711852","citation_count":9,"is_preprint":false},{"pmid":"38267260","id":"PMC_38267260","title":"ISL1 and POU4F1 Directly Interact to Regulate the Differentiation and Survival of Inner Ear Sensory Neurons.","date":"2024","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38267260","citation_count":8,"is_preprint":false},{"pmid":"32474599","id":"PMC_32474599","title":"Brn3a/Pou4f1 Functions as a Tumor Suppressor by Targeting c-MET/STAT3 Signaling in Thyroid Cancer.","date":"2020","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32474599","citation_count":8,"is_preprint":false},{"pmid":"35055045","id":"PMC_35055045","title":"HDAC2 Is Involved in the Regulation of BRN3A in Melanocytes and Melanoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35055045","citation_count":8,"is_preprint":false},{"pmid":"18421303","id":"PMC_18421303","title":"Brn-3a/POU4F1 interacts with and differentially affects p73-mediated transcription.","date":"2008","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/18421303","citation_count":8,"is_preprint":false},{"pmid":"15094508","id":"PMC_15094508","title":"Doppel expression is regulated by the Brn-3a and Brn-3b transcription factors.","date":"2004","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/15094508","citation_count":8,"is_preprint":false},{"pmid":"15818685","id":"PMC_15818685","title":"Elevated expression of the Brn-3a and Brn-3b transcription factors in systemic lupus erythematosus correlates with antibodies to Brn-3 and overexpression of Hsp90.","date":"2005","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/15818685","citation_count":8,"is_preprint":false},{"pmid":"15740807","id":"PMC_15740807","title":"Effect of Brn-3a deficiency on primary nociceptors in the trigeminal ganglion.","date":"2005","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/15740807","citation_count":8,"is_preprint":false},{"pmid":"16040009","id":"PMC_16040009","title":"Brn-3a is required for the generation of proprioceptors in the mesencephalic trigeminal tract nucleus.","date":"2005","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16040009","citation_count":8,"is_preprint":false},{"pmid":"12934100","id":"PMC_12934100","title":"Functional interaction between the small GTP-binding protein Rin and the N-terminal of Brn-3a transcription factor.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12934100","citation_count":8,"is_preprint":false},{"pmid":"18086126","id":"PMC_18086126","title":"Novel Brn3a cis-acting sequences mediate transcription of human trkA in neurons.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18086126","citation_count":7,"is_preprint":false},{"pmid":"21928122","id":"PMC_21928122","title":"Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells.","date":"2011","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21928122","citation_count":7,"is_preprint":false},{"pmid":"15147979","id":"PMC_15147979","title":"EWS differentially activates transcription of the Brn-3a long and short isoform mRNAs from distinct promoters.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15147979","citation_count":7,"is_preprint":false},{"pmid":"37962640","id":"PMC_37962640","title":"Xihuang pill facilitates glioma cell pyroptosis via the POU4F1/STAT3 axis.","date":"2023","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37962640","citation_count":6,"is_preprint":false},{"pmid":"34548095","id":"PMC_34548095","title":"Genetic interplay between transcription factor Pou4f1/Brn3a and neurotrophin receptor Ret in retinal ganglion cell type specification.","date":"2021","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/34548095","citation_count":5,"is_preprint":false},{"pmid":"12598723","id":"PMC_12598723","title":"Unaltered expression of Bcl-2 and TAG-1/axonin-1 precedes sensory apoptosis in Brn3a knockout mice.","date":"2003","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/12598723","citation_count":5,"is_preprint":false},{"pmid":"40122823","id":"PMC_40122823","title":"Deubiquitinase USP18 mediates cell migration, apoptosis and ferroptosis in lung adenocarcinoma by depending on POU4F1/PRKAA2 axis.","date":"2025","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40122823","citation_count":5,"is_preprint":false},{"pmid":"31786755","id":"PMC_31786755","title":"Establishment of resveratrol and its derivatives as neuroprotectant against monocrotophos-induced alteration in NIPBL and POU4F1 protein through molecular docking studies.","date":"2019","source":"Environmental science and pollution research international","url":"https://pubmed.ncbi.nlm.nih.gov/31786755","citation_count":5,"is_preprint":false},{"pmid":"36570085","id":"PMC_36570085","title":"Involvement of Brn3a-positive spinal dorsal horn neurons in the transmission of visceral pain in inflammatory bowel disease model mice.","date":"2022","source":"Frontiers in pain research (Lausanne, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36570085","citation_count":5,"is_preprint":false},{"pmid":"15208987","id":"PMC_15208987","title":"[Effects of lead on the Brn-3a expression and the apoptosis in hippocampus neurons].","date":"2004","source":"Wei sheng yan jiu = Journal of hygiene research","url":"https://pubmed.ncbi.nlm.nih.gov/15208987","citation_count":5,"is_preprint":false},{"pmid":"15194866","id":"PMC_15194866","title":"Distinct domains of Brn-3a regulate apoptosis and neurite outgrowth in vivo.","date":"2004","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/15194866","citation_count":5,"is_preprint":false},{"pmid":"21533495","id":"PMC_21533495","title":"Regulation of neuroblastoma growth and differentiation by the POU family transcription factors Brn-3a and Brn-3b (Review).","date":"1997","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21533495","citation_count":5,"is_preprint":false},{"pmid":"11930150","id":"PMC_11930150","title":"Effect of Brn-3a deficiency on CGRP-immunoreactivity in the dorsal root ganglion.","date":"2002","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/11930150","citation_count":5,"is_preprint":false},{"pmid":"39715266","id":"PMC_39715266","title":"Runx3, Brn3a and Isl1 interplay orchestrates the transcriptional program in the early stages of proprioceptive neuron development.","date":"2024","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39715266","citation_count":4,"is_preprint":false},{"pmid":"38469155","id":"PMC_38469155","title":"Pou4f1-Tbr1 transcriptional cascade controls the formation of Jam2-expressing retinal ganglion cells.","date":"2023","source":"Frontiers in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/38469155","citation_count":4,"is_preprint":false},{"pmid":"20348952","id":"PMC_20348952","title":"EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20348952","citation_count":4,"is_preprint":false},{"pmid":"17325346","id":"PMC_17325346","title":"Brn-3a suppresses pseudorabies virus-induced cell death in sensory neurons.","date":"2007","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/17325346","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48141,"output_tokens":12579,"usd":0.166554,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23630,"output_tokens":5837,"usd":0.132038,"stage2_stop_reason":"end_turn"},"total_usd":0.298592,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Brn-3a encodes two protein isoforms (long and short); the long form containing an intact N-terminal domain (~100 aa conserved among class IV POU factors) is required for oncogenic transformation of primary fibroblasts, whereas the short form (lacking 84 N-terminal residues) cannot transform. Brn-3b can suppress the oncogenic activity of Brn-3a(l) when co-transfected, acting as an inhibitor.\",\n      \"method\": \"Focus-formation assay in primary fibroblasts; co-transfection of long vs. short isoforms and Brn-3a/Brn-3b combinations; identification of conserved N-terminal domain by sequence analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transformation assay with isoform constructs and domain mapping, single lab, two orthogonal approaches (focus formation + sequence analysis)\",\n      \"pmids\": [\"8290353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Brn-3a activates the alpha-internexin promoter via its N-terminal domain, while activation of an artificial promoter containing a synthetic Brn-3a binding site requires only the POU domain. Thus Brn-3a contains two functionally distinct transactivation domains whose activity depends on the target promoter context. Brn-3b represses the alpha-internexin promoter and blocks Brn-3a activation.\",\n      \"method\": \"Co-transfection reporter assays with chimeric Brn-3a/Brn-3b constructs in neuronal and non-neuronal cells; deletion and domain-swap analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic domain-swap mutagenesis with reporter assays, replicated across multiple construct combinations and cell types\",\n      \"pmids\": [\"7852360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The short isoform of Brn-3b (Brn-3b(s)) directly interacts with Brn-3a(l) in solution, preventing Brn-3a(l) from forming stable complexes with octamer-related DNA sequences. This heterodimer is transcriptionally inactive and disrupts preformed Brn-3a(l)-DNA complexes, explaining the antagonistic functional relationship between these isoforms.\",\n      \"method\": \"EMSA (gel mobility shift assay); GST pulldown and in vitro binding studies; co-transfection transcription assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of protein-DNA and protein-protein interactions with multiple orthogonal methods (EMSA, GST pulldown, reporter assays)\",\n      \"pmids\": [\"8537352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Targeted deletion of Brn-3a causes loss of neurons in the trigeminal ganglia, medial habenula, red nucleus, and inferior olivary nucleus, but not in retina or dorsal root ganglia. In trigeminal and dorsal root ganglia (but not retina), loss of Brn-3a markedly reduces expression of Brn-3b and Brn-3c, indicating that Brn-3a positively regulates these paralogous factors in somatosensory neurons.\",\n      \"method\": \"Targeted gene deletion in mice; histological analysis; immunohistochemistry; genetic epistasis (Brn-3a KO effect on Brn-3b/3c expression)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype, replicated across multiple neuronal populations, with downstream transcription factor regulation assessed\",\n      \"pmids\": [\"8876243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The two activation domains of Brn-3a have distinct activities that are dependent on the context of the binding site rather than differences in the target sequence itself. A single-stranded DNA preference for Brn-3a binding was demonstrated for two distinct Brn-3a binding sites.\",\n      \"method\": \"Co-transfection reporter assays with Brn-3a deletion constructs; EMSA with single- and double-stranded DNA; chimeric promoter analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro DNA binding assays with reporter assays, single lab, two orthogonal methods\",\n      \"pmids\": [\"8621561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Brn-3a overexpression in undifferentiated ND7 neuronal cells induces neuronal process outgrowth and activates genes encoding synaptic proteins. These effects are primarily dependent on the POU domain (which also serves as an activation domain), and a single amino acid change in the POU homeodomain of Brn-3a to its Brn-3b equivalent abolishes neurite outgrowth induction. Brn-3b does not induce these effects.\",\n      \"method\": \"Stable overexpression of Brn-3a, Brn-3b, isolated POU domain, and point mutants in ND7 cells; morphological assessment of neurite outgrowth; co-transfection gene expression assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function point mutagenesis, domain deletion, and gain-of-function in neuronal cells with defined morphological readout; multiple orthogonal approaches in one study\",\n      \"pmids\": [\"8972215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Brn-3a overexpression coordinately upregulates all three neurofilament (NF-L, NF-M, NF-H) gene promoters, whereas Brn-3b has no effect. This activation is mediated by the POU domain, and a single amino acid change in the POU homeodomain converts Brn-3b into an activator of neurofilament promoters.\",\n      \"method\": \"Co-transfection reporter assays with neurofilament promoters; Western blot and RT-PCR for endogenous protein/mRNA; domain-swap and point mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — promoter activation assays with point mutants, endogenous protein confirmation, multiple neurofilament genes tested; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"9261145\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Brn-3a directly activates the Bcl-2 P2 promoter in neuronal cells through a specific binding site in the promoter; this activation increases Bcl-2 protein levels. The Brn-3a binding site in the P2 promoter is required for maximal activation and for the response during ND7 cell differentiation.\",\n      \"method\": \"Co-transfection reporter assays; EMSA; Western blot for BCL-2 protein; stable Brn-3a overexpression lines; primary DRG neurons\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct DNA binding (EMSA), endogenous protein upregulation, promoter deletion/mutation, multiple cell types including primary neurons\",\n      \"pmids\": [\"9642226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Brn-3a and Brn-3b POU domains interact with the DNA-binding domain of the estrogen receptor (ER) independently of ligand. In estradiol-stimulated cells, Brn-3b strongly activates an ERE-containing promoter whereas Brn-3a has a mild inhibitory effect. A single amino acid change in the first helix of the Brn-3a POU homeodomain to the Brn-3b equivalent converts its mild repression to Brn-3b-like activation.\",\n      \"method\": \"GST pulldown assay; yeast two-hybrid; co-transfection reporter assays with ERE-containing promoter; point mutagenesis of POU homeodomain\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro binding confirmed by two independent methods (pulldown + Y2H), functional consequence tested with mutagenesis, single lab\",\n      \"pmids\": [\"9448000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Brn-3a strongly activates Bcl-2 promoter activity and this activation is inhibited by p53. p53 requires DNA-binding activity for this inhibitory effect (DNA-binding mutants of p53 do not inhibit). Brn-3a and p53 bind to adjacent sites in the Bcl-2 p2 promoter and directly interact in vitro and in vivo; this interaction is mediated by the POU domain of Brn-3a and the DNA-binding domain of p53. The inhibitory effect is specific to Bcl-2 p1/p2 promoters and not observed on other Brn-3a-activated promoters.\",\n      \"method\": \"Co-transfection reporter assays; in vitro GST pulldown; co-immunoprecipitation in vivo; EMSA; promoter deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro and in vivo protein-protein interaction confirmed by GST pulldown and co-IP, domain mapping with mutants, promoter specificity tested\",\n      \"pmids\": [\"10329733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Brn-3a controls survival and differentiation of trigeminal neurons by regulating expression of all three Trk receptors. In Brn-3a-null mice, TrkC-expressing neurons are almost absent from birth, TrkB neurons are transiently elevated then lost, and TrkA expression progressively declines after E12.5, leading to massive apoptosis peaking at E15.5. Surviving neurons predominantly express c-ret and can be sustained by GDNF but not NGF, indicating Brn-3a does not regulate GDNF receptor expression.\",\n      \"method\": \"Brn-3a knockout mice; immunohistochemistry for Trk receptors; TUNEL apoptosis assay; in vitro neurotrophic factor survival assays on KO neurons; temporal staging\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined molecular targets (three Trk receptors), temporal analysis, functional rescue experiments in culture\",\n      \"pmids\": [\"10357931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Brn-3a is a transcriptional regulator of soma size, neuronal migration, and axon pathfinding in the inner ear. Absence of Brn-3a causes downregulation of TrkC, parvalbumin, and Brn-3b; selective loss of TrkC-expressing spiral ganglion neurons (phenocopying TrkC-/- mice); and severe retardation of axon projections to the cochlea and posterior vertical canal by E13.5, as well as misrouting of efferent axons.\",\n      \"method\": \"Brn-3a knockout mouse analysis; immunohistochemistry; DiI axon tracing; temporal staging; comparison with TrkC KO phenotype\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO, multiple downstream targets identified, phenotypic comparison with known pathway component (TrkC KO), axonal tracing\",\n      \"pmids\": [\"11493560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Brn-3a directly activates the Bcl-xL promoter in sensory but not sympathetic neurons; antisense reduction of Brn-3a reduces Bcl-xL expression; overexpression of Brn-3a in DRG in vivo (sciatic nerve injury model) enhances both Bcl-xL expression and neuronal survival.\",\n      \"method\": \"Co-transfection reporter assays; antisense oligonucleotides; in vivo Brn-3a overexpression via injection; Western blot; survival counting in DRG\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo overexpression with functional readout, antisense KD, reporter assays; single lab, multiple methods\",\n      \"pmids\": [\"11273642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Brn-3a minimal promoter in the Bcl-xL locus is activated by Brn-3a and this activation is specifically blocked by p53. The same promoter sequences required for basal activity mediate both Brn-3a activation and p53 repression. A second upstream Bcl-xL promoter is also activated by Brn-3a and repressed by p53.\",\n      \"method\": \"Co-transfection reporter assays with Bcl-xL promoter deletions; co-expression of Brn-3a and p53\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter functional dissection with deletion analysis, single lab, two promoter regions tested\",\n      \"pmids\": [\"11713302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Sensory axon growth defects (excessive/premature branching, failure to innervate whisker follicles) precede neuronal death in Brn-3a null mice. These defects resemble those in semaphorin 3A and neuropilin-1 null mice; however, neuropilin-1 expression is maintained in Brn-3a-null sensory neurons, indicating Brn-3a controls axon pathfinding through other downstream genes.\",\n      \"method\": \"Brn-3a KO crossed to LacZ reporter transgene; whole-mount beta-galactosidase histochemistry for axon visualization; immunohistochemistry for neuropilin-1; temporal analysis of phenotype vs. cell death\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — LacZ-based axon tracing in KO background, temporal dissection of phenotype, molecular marker analysis; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"11160433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Overexpression of Brn-3a in cultured trigeminal and DRG sensory neurons enhances survival after NGF withdrawal and activates the endogenous Bcl-2 gene; reducing Brn-3a levels with antisense impairs survival of these neurons. The protective effect is absent in sympathetic neurons. Brn-3b can promote early-stage trigeminal neuron survival but with less temporal breadth than Brn-3a.\",\n      \"method\": \"Primary neuronal cultures from TG and DRG; overexpression via plasmid transfection; antisense reduction; NGF withdrawal survival assay; Bcl-2 protein measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in primary neurons with survival readout, cell-type specificity demonstrated; single lab\",\n      \"pmids\": [\"11053412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Brn-3a abolishes p53-mediated activation of the pro-apoptotic Bax promoter and Bax protein expression, while cooperating with p53 to maximally activate the p21(CIP1/Waf1) promoter. At the cellular level, Brn-3a antagonizes p53-induced apoptosis but cooperates with p53 to induce cell cycle arrest.\",\n      \"method\": \"Co-transfection reporter assays with Bax and p21 promoters; Western blot for Bax and p21 protein; apoptosis and cell cycle assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter + protein level + cellular phenotype; single lab, multiple readouts\",\n      \"pmids\": [\"12203124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Brn-3a directly binds to specific sites in a 457 bp enhancer that regulates TrkA expression in embryonic sensory neurons. Mutagenesis of these Brn-3a binding sites in the enhancer abolishes appropriate reporter transgene expression in sensory neurons in vivo. Using Bax-KO mice to uncouple cell death from TrkA downregulation confirmed that Brn-3a is required for maintaining TrkA transcriptional activity independently of neurotrophin-dependent survival.\",\n      \"method\": \"EMSA; transgenic reporter mice with mutagenized enhancer; Bax-KO genetic background epistasis; in vivo transgene expression analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro DNA binding + in vivo enhancer mutagenesis + genetic epistasis with Bax-KO; multiple orthogonal approaches\",\n      \"pmids\": [\"12810599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Brn-3a negatively autoregulates its own expression by binding to conserved sites within an 11 kb upstream enhancer. In Brn-3a(+/-) mice, expression of the remaining allele is upregulated to near wild-type levels (gene dosage compensation), while transgenic overexpression of Brn-3a suppresses the endogenous gene.\",\n      \"method\": \"LacZ reporter transgenes; in vivo chromatin-binding analysis; comparison of Brn-3a protein levels in +/+, +/-, and -/- mice; transgenic overexpression\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo evidence from multiple genetic backgrounds, gain-of-function and loss-of-function, site mutagenesis in transgene\",\n      \"pmids\": [\"12441296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"EWS (Ewing's Sarcoma protein) interacts with Brn-3a via the POU domain and the RNA-binding domain of EWS (in vitro), and EWS inhibits Brn-3a-mediated activation of the Bcl-xL promoter.\",\n      \"method\": \"Yeast two-hybrid screen; in vitro GST pulldown; co-transfection reporter assays\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus GST pulldown (two orthogonal in vitro binding methods) plus reporter assay; single lab\",\n      \"pmids\": [\"12432261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"HIPK2 physically interacts with Brn-3a, promotes Brn-3a DNA binding, but suppresses Brn-3a-dependent transcription of brn3a, trkA, and bcl-xL target genes. HIPK2 overexpression induces apoptosis in sensory neurons, while HIPK2 KO increases Brn-3a, TrkA, and Bcl-xL expression and reduces apoptosis in the trigeminal ganglion.\",\n      \"method\": \"Co-immunoprecipitation; EMSA; co-transfection reporter assays; HIPK2 overexpression in primary sensory neurons; HIPK2 targeted deletion mouse; immunohistochemistry; TUNEL\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, functional reporter assays, and in vivo KO with defined phenotype; multiple orthogonal methods in one study\",\n      \"pmids\": [\"15492043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Brn-3a abolishes p53-mediated transcription of the pro-apoptotic gene Noxa. EMSA studies show Brn-3a is associated with p53 when p53 is bound to the Noxa promoter. ChIP confirms Brn-3a association with the wild-type but not mutant Noxa promoter in cells. Co-expression of Brn-3a with p53 reduces endogenous Noxa protein in ND7 neuronal cells. In Brn-3a-/- embryos, both Bax and Noxa proteins are elevated at E14.5, preceding the wave of neuronal apoptosis.\",\n      \"method\": \"Co-transfection reporter assays; EMSA; ChIP; Western blot for endogenous Noxa and Bax; Brn-3a KO embryo tissue analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP confirms genomic occupancy, EMSA shows protein-DNA association, endogenous protein changes validated, in vivo KO confirmation\",\n      \"pmids\": [\"15598651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The N-terminal transcriptional activation domain of Brn-3a is essential for neuronal survival in vivo, while the POU domain is essential for neurite outgrowth in vivo. These two functions are thus controlled by separable domains of the protein.\",\n      \"method\": \"In vivo gene manipulation (domain-specific Brn-3a constructs introduced into mice); neuronal survival quantification; neurite morphology assessment\",\n      \"journal\": \"Neuroreport\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo domain manipulation, two distinct readouts; single lab\",\n      \"pmids\": [\"15194866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"EWS/Fli-1 (but not EWS alone) interacts with Brn-3a via the C-terminal POU domain. EWS/Fli-1 overexpression specifically inhibits Brn-3a-associated growth arrest and neurite outgrowth and blocks Brn-3a-dependent activation of p21 and SNAP-25 transcription, while EWS more effectively antagonizes the Bcl-2 upregulation function of Brn-3a.\",\n      \"method\": \"In vitro GST pulldown; co-transfection reporter assays for p21 and SNAP-25; neurite outgrowth and growth arrest assays in neuronal cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro protein interaction plus multiple functional readouts in cells; single lab\",\n      \"pmids\": [\"15021903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Rin, a neuron-specific small GTP-binding protein, physically interacts with the N-terminal domain of Brn-3a (identified by yeast two-hybrid) and modulates Brn-3a N-terminal-dependent activation of the egr-1 promoter.\",\n      \"method\": \"Yeast two-hybrid screen; co-transfection reporter assays for egr-1 promoter; N-terminal domain of Brn-3a as bait\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — yeast two-hybrid plus reporter assay, interaction not confirmed by independent method (e.g., co-IP in mammalian cells); single lab\",\n      \"pmids\": [\"12934100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Brn-3a-expressing RGCs project specifically to the principal retinothalamic/retinocollicular pathway (thalamocortical and collicular visual pathways) and are absent from RGCs serving accessory optic, pretectal, and hypothalamic (circadian) pathways. Brn-3a RGC axons preferentially project to the outer shell of the dorsal lateral geniculate nucleus contralaterally.\",\n      \"method\": \"Targeted knock-in of tau/beta-galactosidase axonal tracer into the Brn3a locus; anterograde axon tracing; Brn-3a KO analysis of laterality\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic axonal tracing with specific reporter, multiple CNS targets analyzed, KO controls\",\n      \"pmids\": [\"16354917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Brn-3a is a direct repressor of NeuroD1 and NeuroD4 (pro-neurogenic genes) in embryonic sensory neurons, and also directly modulates its own expression. Locus-wide ChIP in embryonic trigeminal neurons shows that in vivo Brn-3a binding correlates with evolutionary conservation of genomic regions and with active histone modifications (H3 acetylation); not all high-affinity sites are occupied in vivo.\",\n      \"method\": \"Locus-wide ChIP in embryonic trigeminal neurons; microarray expression profiling of Brn3a-null ganglia; correlation of binding with histone marks and evolutionary conservation\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP in primary embryonic neurons, combined with expression profiling; chromatin state and evolutionary conservation analysis\",\n      \"pmids\": [\"17196582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Brn-3a and Klf7 synergistically activate the TrkA enhancer in vitro. In double Brn-3a-/-;Klf7-/- mutants, TrkA expression is severely reduced at E12.5 and completely lost by birth (more severe than either single mutant), demonstrating cooperative regulation of endogenous TrkA expression required for nociceptive sensory neuron survival.\",\n      \"method\": \"Co-transfection reporter assays (synergistic activation); Brn-3a-/-;Klf7-/- double KO mice; in vivo TrkA expression by immunohistochemistry; genetic epistasis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in double KO, in vitro synergy assay, in vivo expression readout; well-controlled study\",\n      \"pmids\": [\"17011544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The MEK1/2-ERK1/2 signaling pathway regulates Brn-3a N-terminal transcriptional activity during retinoic acid (RA)-mediated neuronal differentiation. Phosphorylation of Brn-3a at serine-122 (and threonine-39) is required for RA-induced neurite outgrowth and N-terminal transactivation of the Galanin promoter. MEK inhibitors block both RA-induced Galanin activation and Brn-3a N-terminal activity; constitutively active MEK1 (but not MEK5) is sufficient to increase Brn-3a activity.\",\n      \"method\": \"Site-directed mutagenesis of Brn-3a (S122A, T39A); co-transfection reporter assays with Galanin promoter; pharmacological MEK inhibition; constitutively active MEK1/MEK5 expression; neurite outgrowth assay in ND7 cells\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis of phosphorylation sites with functional readout, pathway inhibitors, gain-of-function kinase; single lab\",\n      \"pmids\": [\"19135033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Brn-3a physically interacts with TAp73 and ΔNp73 isoforms and co-localizes with them in sensory neurons. Brn-3a antagonizes TAp73-mediated transactivation of pro-apoptotic Bax but cooperates with TAp73 to activate p21(CIP1/Waf1). Co-expression with ΔNp73 increases apoptotic protection. The C-terminal region (aa 425-494) of TAp73 is critical for Brn-3a to repress Bax transactivation.\",\n      \"method\": \"Co-immunoprecipitation; immunofluorescence co-localization; co-transfection reporter assays with Bax and p21 promoters; TAp73 C-terminal deletion constructs\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP in cells, domain mapping, multiple functional readouts; single lab\",\n      \"pmids\": [\"18421303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Brn-3a-expressing habenular neurons project exclusively to the interpeduncular nucleus. In Brn-3a null embryos, the fasciculus retroflexus forms correctly but habenular neurons fail to innervate their targets. Microarray analysis of Brn-3a null embryos reveals that Brn-3a regulates an extensive program of habenula-enriched genes. The orphan nuclear receptor Nurr1/Nr4a2 is downstream of Brn-3a and mediates expression of a subset of Brn-3a-regulated habenular transcripts.\",\n      \"method\": \"Brn-3a KO mice; axon tracing; microarray gene expression profiling; genetic epistasis (Nurr1 expression in Brn-3a nulls); bioinformatic analysis\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO with axon tracing, genome-wide expression profiling, genetic epistasis for downstream factor; multiple orthogonal methods\",\n      \"pmids\": [\"19906978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Brn-3a and Brn-3b control overlapping but distinct aspects of RGC development. Brn-3a deletion alters dendritic stratification and the monostratified:bistratified RGC ratio with little effect on central projections. Brn-3b deletion leads to RGC transdifferentiation and loss, axon defects, and disrupted central projections affecting multiple visually driven behaviors. Both factors are thus required for programming distinct aspects of RGC diversity.\",\n      \"method\": \"Conditional KO alleles of Brn-3a and Brn-3b with visualization of individual cells; dendritic morphology and stratification analysis; anterograde axon tracing; behavioral testing (visual tasks)\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with single-cell morphology, axon tracing, and behavior; well-controlled dissection of two factors\",\n      \"pmids\": [\"19323995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Brn-3a acts upstream of Runx transcription factors to specify sensory neuron subtypes in the trigeminal ganglion. In Brn-3a-/- embryos, Runx3 expression is never initiated in TrkC+ neurons and Runx1 expression is severely reduced in TrkA+ neurons. A Brn-3a-VP16 dominant transactivator increases Runx3 mRNA, and Brn-3a binds in vivo by ChIP to a conserved upstream enhancer within H3-acetylated chromatin at the Runx3 locus.\",\n      \"method\": \"Brn-3a KO mice; Brn-3a-VP16 transgenic mice; ChIP for Brn-3a at Runx3 locus; immunohistochemistry for Trk receptors and Runx factors; histone modification analysis\",\n      \"journal\": \"Neural development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP in vivo, gain-of-function (VP16 transactivator) and loss-of-function (KO), histone acetylation context; multiple orthogonal methods\",\n      \"pmids\": [\"20096094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Brn-3a is required for DRG sensory neuron subtype specification and for central axon projections into the spinal cord. Brn-3a-null DRGs show excessive early generation of TrkB+ and TrkC+ neurons plus double-positive (TrkA+/TrkB+ and TrkA+/TrkC+) cells, followed by loss of TrkB+, TrkC+ and parvalbumin+ neurons and increases in CGRP+ and c-ret+ neurons. TrkA+ afferents fail to enter the dorsal horn and TrkC+ proprioceptive projections to the ventral horn are impaired. Runx1 expression is dramatically downregulated, suggesting Brn-3a acts through Runx1 for specification.\",\n      \"method\": \"Brn-3a single and Brn-3a;Brn-3b double KO mice; immunohistochemistry for Trk receptors, parvalbumin, CGRP, Runx1; DiI axon tracing; temporal staging\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — double and single KO, multiple molecular markers, axon tracing, temporal analysis; epistasis with Runx1\",\n      \"pmids\": [\"22326227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Pou4f1 defines a subpopulation of modiolar-side type I spiral ganglion neurons (SGNs). Conditional deletion of Pou4f1 in SGNs after E13 (avoiding early pathfinding/apoptosis phenotypes) alters Ca2+ channel activation in inner hair cells (IHCs), increasing voltage sensitivity and eliminating the normal modiolar-to-pillar gradient of active zone Ca2+ influx strength, without changing SGN numbers, morphology, or synapse distribution.\",\n      \"method\": \"Conditional KO of Pou4f1 in SGNs (tamoxifen-inducible Cre); immunohistochemistry; Ca2+ imaging of IHC active zones; patch-clamp electrophysiology of IHC Ca2+ channels\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with electrophysiology and Ca2+ imaging readouts, multiple controls to separate developmental from mature function\",\n      \"pmids\": [\"31085606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Pou4f1 (Brn3a) is a Smad3 target gene and key downstream regulator of macrophage-myofibroblast transition (MMT) in renal fibrosis. ChIP confirmed Pou4f1 as a Smad3 target. Microarray defined a Pou4f1-dependent fibrogenic gene network driving TGF-β1/Smad3-induced MMT. Silencing Pou4f1 in TGF-β1-stimulated bone marrow-derived macrophages, then adoptively transferring them, prevented restoration of MMT and fibrosis in macrophage-depleted mice.\",\n      \"method\": \"ChIP (Smad3 binding to Pou4f1 locus); microarray gene expression; siRNA silencing; in vitro MMT assay; adoptive transfer of BMDMs into macrophage-depleted mice; two mouse models of renal fibrosis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP, genome-wide expression profiling, in vitro and in vivo functional rescue with KD; multiple orthogonal approaches and two disease models\",\n      \"pmids\": [\"32788346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"POU4F1 promotes BRAF-inhibitor resistance in melanoma by transcriptionally activating MEK expression to re-activate the MAPK/ERK pathway and by increasing MITF expression.\",\n      \"method\": \"POU4F1 overexpression and knockdown in melanoma cells; Western blot for MEK, ERK, MITF; luciferase reporter assays for MEK promoter; xenograft mouse models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with reporter assay for MEK promoter and in vivo xenograft; single lab\",\n      \"pmids\": [\"32532957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HDAC2 represses BRN3A expression in melanocytes and melanoma by maintaining deacetylated chromatin at a distal enhancer of the BRN3A gene. Selective HDAC2 siRNA knockdown increases H3K27ac levels at this BRN3A distal enhancer (confirmed by ChIP-Seq) and upregulates BRN3A expression.\",\n      \"method\": \"siRNA knockdown of individual HDACs; ChIP-Seq for H3K27ac; pharmacological HDAC inhibitors (class-selective and isoform-selective); RT-PCR and Western blot for BRN3A\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-Seq identifying specific enhancer, isoform-selective siRNA, pharmacological validation; single lab\",\n      \"pmids\": [\"35055045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ISL1 and POU4F1 directly interact in developing cochleovestibular ganglion (CVG) neurons and cooperate to regulate expression of CVG-specific genes. Compound Isl1;Pou4f1 double KO causes near-complete loss of spiral ganglion neurons—more severe than either single KO—with defects in migration, axon pathfinding, and survival. POU4F1 directly binds cis-regulatory elements of Fgf10, Pou4f2, Epha5 (promoters) and Eya1 and Ntng2 (enhancers).\",\n      \"method\": \"Isl1 and Pou4f1 single and double KO mice; immunohistochemistry; co-immunoprecipitation of ISL1-POU4F1; ChIP for POU4F1 at target loci; gene expression profiling\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — co-IP demonstrating direct interaction, ChIP at multiple target loci, double KO genetic epistasis with quantitative phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"38267260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"POU4F1 is required for G1/S cell cycle progression in basal-like breast cancer (BLBC) through direct binding at the promoters of CDK2 and CCND1. POU4F1 also maintains BLBC identity by repressing ESR1 (ERα) expression through CDK2-mediated EZH2 phosphorylation and subsequent H3K27me3 modification at the ESR1 promoter. POU4F1 promoter activation in BLBC is maintained by the DNA demethylase TET1, which reconfigures bivalent chromatin to an active state.\",\n      \"method\": \"POU4F1 KO in BLBC cells; ChIP for POU4F1 at CDK2 and CCND1 promoters; cell cycle and proliferation assays; H3K27me3 ChIP at ESR1; Western blot for ERα and EZH2 phosphorylation; TET1 knockdown and DNA methylation analysis\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP at direct target promoters, KO phenotype, mechanistic pathway (CDK2-EZH2-H3K27me3) validated with multiple orthogonal methods; single lab rigorous study\",\n      \"pmids\": [\"38491910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Pou4f1 acts as a transcription factor for STAT3, directly regulating STAT3 transcription. In glioma cells, POU4F1 overexpression or STAT3 silencing suppresses XHP-induced pyroptosis, placing Pou4f1 upstream of STAT3 in this pathway.\",\n      \"method\": \"Dual-luciferase reporter assay for STAT3 promoter; co-IP of POU4F1-STAT3; Western blot; ChIP; siRNA/overexpression in glioma cell lines; in vivo glioma model\",\n      \"journal\": \"Functional & integrative genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay + ChIP + co-IP confirm direct transcriptional regulation of STAT3; in vivo corroboration; single lab\",\n      \"pmids\": [\"37962640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Pou4f1 directly binds to the Tbr1 locus (exon 6 and 3'UTR flanking region) and to the Jam2 promoter region; Pou4f1 is required for expression of Tbr1 and Jam2 in J-RGCs. The Pou4f1-bound element in Tbr1 exon 6 has enhancer activity capable of directing reporter expression in J-RGCs, establishing a Pou4f1-Tbr1-Jam2 transcriptional cascade for J-RGC subtype formation.\",\n      \"method\": \"CUT&RUN (Cleavage Under Targets and Tagmentation); conditional KO of Pou4f1; reporter assay for enhancer activity; immunohistochemistry for Tbr1 and Jam2; in situ hybridization\",\n      \"journal\": \"Frontiers in ophthalmology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — CUT&RUN identifies direct binding sites, KO confirms functional requirement, enhancer reporter validates activity; multiple orthogonal methods\",\n      \"pmids\": [\"38469155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Runx3 and Brn3a co-bind to numerous genomic loci in early TrkC proprioceptive neurons, primarily at distally located enhancer regions. In activated and suppressed neuronal Runx3 high-confidence target genes, Runx3 cooperates mainly with Brn3a to regulate gene expression through these distant enhancers, while suppression of non-neuronal immune genes is managed by Runx3 without Brn3a.\",\n      \"method\": \"CUT&RUN for Runx3, Brn3a, Isl1, and H3K27Ac; ATAC-seq; RNA-seq of heterozygous vs. homozygous P2-Runx3 TrkC neurons; bioinformatic co-occupancy analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CUT&RUN and ATAC-seq for genomic occupancy, transcriptome for target gene identification; functional validation is indirect (KO of Runx3, not Brn3a); single study\",\n      \"pmids\": [\"39715266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"USP18 stabilizes POU4F1 protein through deubiquitination. POU4F1 in turn promotes transcription of PRKAA2 (AMPK-α2) by binding its promoter (ChIP and dual-luciferase confirmed). USP18-mediated oncogenic effects in lung adenocarcinoma are reversed by POU4F1 knockdown, and POU4F1 regulates cell behaviors via PRKAA2 upregulation.\",\n      \"method\": \"Immunoprecipitation and ubiquitination assay (USP18-POU4F1 interaction); ChIP and dual-luciferase reporter for POU4F1 at PRKAA2 promoter; siRNA/overexpression; xenograft mouse model\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay + ChIP + reporter for transcriptional regulation, in vivo xenograft; single lab\",\n      \"pmids\": [\"40122823\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"POU4F1/Brn3a is a class IV POU-domain transcription factor that exists as two functionally distinct isoforms (long and short); the long isoform uses an N-terminal transactivation domain to activate anti-apoptotic genes (Bcl-2, Bcl-xL) and protect sensory neurons from apoptosis, while the POU domain drives neurite outgrowth, neurofilament gene expression, and direct DNA binding at target promoters including TrkA, TrkC, Runx3, Tbr1, CDK2, CCND1, and PRKAA2; Brn-3a directly interacts with and differentially modulates the pro-apoptotic transcription factors p53, p73, and HIPK2 (which promotes DNA binding but suppresses transcription), ISL1 (cooperative partner in sensory ganglion development), EWS, and the estrogen receptor; it negatively autoregulates its own expression through upstream enhancer binding; in developing neurons it acts upstream of Runx factors and Nurr1 to specify sensory and habenular neuron subtypes, controls axon pathfinding in trigeminal, spiral, and retinal ganglion cells, and defines functionally distinct RGC subtypes projecting to specific visual targets; in non-neuronal contexts (macrophages, melanoma, leukemia, breast cancer, kidney fibrosis) it regulates fibrogenesis as a Smad3 target, melanoma survival through DNA damage checkpoints, BRAF-inhibitor resistance via MEK transcription, and basal-like breast cancer maintenance through CDK2-EZH2-mediated ERα silencing.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"POU4F1 (Brn-3a) is a class IV POU-domain transcription factor that governs survival, differentiation, and subtype identity of sensory and central neurons, and is redeployed in several non-neuronal disease contexts [#3, #26]. It is expressed as two functionally distinct isoforms: the long form carries an N-terminal transactivation domain required for oncogenic transformation and for neuronal survival in vivo, whereas the POU domain mediates DNA binding, neurite outgrowth, and neurofilament/synaptic gene activation—two separable activities whose output depends on target-promoter context and a single critical residue in the POU homeodomain that distinguishes Brn-3a from its antagonistic paralog Brn-3b [#0, #1, #5, #6, #22]. The protein binds DNA directly at target promoters and enhancers and supports a pro-survival program by transactivating the anti-apoptotic genes Bcl-2 and Bcl-xL [#7, #12]. This survival arm is integrated with apoptotic control through direct interaction with the POU domain: Brn-3a binds p53, p73, and HIPK2 to selectively block transactivation of pro-apoptotic targets (Bax, Noxa) while cooperating on the cell-cycle arrest gene p21, and HIPK2 promotes its DNA binding yet suppresses its transcriptional output [#9, #16, #20, #21, #29]. In sensory neuron development, Brn-3a directly maintains TrkA, TrkB, and TrkC receptor expression—acting at a TrkA enhancer cooperatively with Klf7—and operates upstream of Runx factors and Nurr1 to specify neuronal subtypes while repressing the proneural genes NeuroD1/NeuroD4; its in vivo occupancy correlates with conserved, H3-acetylated chromatin [#10, #17, #26, #27, #32]. It directs axon pathfinding and target innervation in trigeminal, spiral, habenular, and retinal ganglion neurons, defines functionally distinct RGC subtypes through a Pou4f1-Tbr1-Jam2 cascade, and cooperates with ISL1 to program cochleovestibular ganglion identity [#3, #11, #25, #30, #31, #38, #41]. Brn-3a negatively autoregulates its own expression via an upstream enhancer, and its activity is tuned by MEK1/2-ERK phosphorylation at serine-122 [#18, #28]. In disease settings it serves as a Smad3 target driving macrophage-myofibroblast transition in renal fibrosis, promotes BRAF-inhibitor resistance in melanoma by transactivating MEK, and maintains basal-like breast cancer by activating CDK2/CCND1 and silencing ESR1 through a CDK2-EZH2-H3K27me3 axis [#35, #36, #39].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that Brn-3a is a bifunctional transcription factor with two separable activation domains whose use is dictated by promoter context, and that the antagonist Brn-3b acts by direct heterodimerization that blocks Brn-3a DNA binding—defining the molecular basis of the Brn-3a/Brn-3b functional opposition.\",\n      \"evidence\": \"Domain-swap reporter assays plus EMSA and GST pulldown showing Brn-3b(s)–Brn-3a(l) complex formation in vitro\",\n      \"pmids\": [\"7852360\", \"8537352\", \"8290353\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous stoichiometry of Brn-3a/Brn-3b heterodimers in neurons not quantified\", \"Structural basis of context-dependent activation-domain choice not resolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined the in vivo requirement for Brn-3a in specific neuronal populations and revealed it sits atop a transcription-factor hierarchy by positively regulating its paralogs in somatosensory neurons.\",\n      \"evidence\": \"Targeted Brn-3a deletion in mice with histology and analysis of Brn-3b/3c expression\",\n      \"pmids\": [\"8876243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. indirect regulation of Brn-3b/3c not distinguished at this stage\", \"Molecular targets causing neuronal loss not yet identified\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Mapped neurite outgrowth and neurofilament/synaptic gene activation to the POU domain and pinpointed a single homeodomain residue that confers Brn-3a-specific activity, explaining functional divergence from Brn-3b.\",\n      \"evidence\": \"Overexpression, domain deletion, and point mutagenesis in ND7 cells with morphological and promoter-reporter readouts\",\n      \"pmids\": [\"8972215\", \"9261145\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct genomic targets mediating outgrowth in vivo not defined\", \"How a single residue alters DNA/cofactor selectivity unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified Bcl-2 as a direct Brn-3a target, linking the transcription factor to a defined anti-apoptotic survival mechanism, and showed POU-domain interaction with the estrogen receptor extends its regulatory reach.\",\n      \"evidence\": \"EMSA, promoter-reporter assays, Western blot for endogenous BCL-2; GST pulldown and Y2H for ER interaction\",\n      \"pmids\": [\"9642226\", \"9448000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement of the Bcl-2 site for neuronal survival not directly tested here\", \"Physiological relevance of ER interaction in neurons unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Revealed that Brn-3a directly engages p53 to selectively suppress apoptosis while sparing other targets, defining a mechanism by which a neuronal survival factor restrains a pro-apoptotic transcription factor.\",\n      \"evidence\": \"GST pulldown, co-IP, EMSA, and promoter-deletion reporter assays mapping POU–p53 DNA-binding-domain interaction\",\n      \"pmids\": [\"10329733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the Brn-3a–p53 complex on DNA not resolved\", \"Genome-wide scope of selective p53 antagonism not assessed at this stage\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Extended the survival program to Bcl-xL and demonstrated cell-type specificity (sensory but not sympathetic neurons), establishing Brn-3a as a context-dependent neuroprotective regulator in vivo.\",\n      \"evidence\": \"Reporter assays, antisense knockdown, in vivo DRG overexpression with survival counts, and Bcl-xL promoter dissection under p53 repression\",\n      \"pmids\": [\"11273642\", \"11713302\", \"11053412\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic basis of sensory vs. sympathetic specificity not defined\", \"Single-lab in vivo overexpression data\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Separated axon-pathfinding defects from neuronal death temporally, establishing that Brn-3a controls trigeminal, spiral, and inner-ear axon guidance through downstream genes other than the semaphorin/neuropilin axis.\",\n      \"evidence\": \"Brn-3a KO with LacZ axon tracing, DiI tracing, and marker analysis with temporal staging\",\n      \"pmids\": [\"11160433\", \"11493560\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct downstream pathfinding effectors not identified\", \"Mechanism distinguishing guidance from survival functions unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Clarified that Brn-3a partitions p53 outputs—blocking apoptosis (Bax/Noxa) while cooperating on cell-cycle arrest (p21)—giving a coherent model for how it shifts cell fate decisions.\",\n      \"evidence\": \"Promoter-reporter assays, protein-level measurements, and apoptosis/cell-cycle assays; later EMSA/ChIP for Noxa promoter occupancy\",\n      \"pmids\": [\"12203124\", \"15598651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Brn-3a converts p53 from apoptotic to arrest mode at the promoter level not fully resolved\", \"Generality across p53 target promoters not exhaustively mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated direct in vivo enhancer occupancy and uncoupled transcriptional maintenance of TrkA from survival using Bax-KO epistasis, and established negative autoregulation as a dosage-control mechanism.\",\n      \"evidence\": \"EMSA, transgenic enhancer-mutagenesis reporter mice, Bax-KO epistasis, and autoregulation analysis across Brn-3a genotypes\",\n      \"pmids\": [\"12810599\", \"12441296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors required for enhancer-specific occupancy in vivo not fully defined\", \"Mechanism of autorepression at the chromatin level not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Expanded the interaction network to HIPK2, p73, EWS, and EWS/Fli-1, revealing that partners can uncouple DNA binding from transcriptional output and modulate the survival/differentiation balance.\",\n      \"evidence\": \"Co-IP, EMSA, reporter assays, HIPK2 KO mouse phenotyping, and GST pulldown for EWS/EWS-Fli-1 interactions\",\n      \"pmids\": [\"15492043\", \"18421303\", \"12432261\", \"15021903\", \"15194866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which HIPK2 promotes binding yet suppresses transcription not structurally defined\", \"Physiological relevance of EWS/EWS-Fli-1 interactions outside overexpression contexts uncertain\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Provided a genome-scale view: in vivo Brn-3a occupancy tracks evolutionary conservation and active histone marks, and Brn-3a acts as a direct repressor of proneural genes, refining its role as a context-selective regulator rather than a simple activator.\",\n      \"evidence\": \"Locus-wide ChIP in embryonic trigeminal neurons combined with expression profiling and chromatin-state correlation\",\n      \"pmids\": [\"17196582\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of in vivo site selection beyond conservation/histone state not defined\", \"Repressor mechanism at NeuroD loci not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed Brn-3a in a transcriptional hierarchy upstream of Runx factors and Nurr1, establishing it as a master regulator of sensory and habenular neuron subtype specification through direct enhancer binding.\",\n      \"evidence\": \"KO and VP16-transactivator mice, in vivo ChIP at the Runx3 locus, axon tracing, and microarray epistasis for Nurr1\",\n      \"pmids\": [\"20096094\", \"19906978\", \"17011544\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Combinatorial logic with Runx/Nurr1 not fully resolved\", \"Direct vs. indirect targets within subtype programs not all distinguished\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated that Brn-3a is required for DRG subtype diversification and central afferent projections, with Runx1 as a downstream specification mediator, extending the developmental program to the spinal sensory system.\",\n      \"evidence\": \"Single and Brn-3a;Brn-3b double KO mice with marker analysis, DiI tracing, and temporal staging\",\n      \"pmids\": [\"22326227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Runx1 regulation in DRG not shown by ChIP here\", \"Effectors of central axon entry not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Distinguished a mature, post-developmental function: Pou4f1 tunes inner-hair-cell Ca2+ channel properties and the modiolar–pillar activity gradient in spiral ganglion neurons independent of its earlier survival/pathfinding roles.\",\n      \"evidence\": \"Tamoxifen-inducible conditional KO after E13 with Ca2+ imaging and patch-clamp electrophysiology\",\n      \"pmids\": [\"31085606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets mediating the Ca2+ phenotype not identified\", \"Cell-autonomous vs. retrograde signaling basis unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined RGC and cochleovestibular subtype programs at the level of direct binding, including a Pou4f1-Tbr1-Jam2 cascade and ISL1 cooperativity, sharpening the model of combinatorial subtype specification.\",\n      \"evidence\": \"CUT&RUN/ChIP for direct targets, conditional and double KO genetic epistasis, co-IP of ISL1-POU4F1, and enhancer reporter assays\",\n      \"pmids\": [\"38469155\", \"38267260\", \"39715266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full target catalog of each cooperative partnership incomplete\", \"Brn3a-specific functional validation in the Runx3 co-occupancy study is indirect\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established disease-context roles in which POU4F1 is itself regulated (Smad3 transactivation, HDAC2/TET1 chromatin control, USP18 deubiquitination) and drives fibrogenic, drug-resistance, oncogenic-proliferation, and identity programs through direct target promoters.\",\n      \"evidence\": \"ChIP/CUT&RUN at MEK, CDK2/CCND1, ESR1, STAT3, PRKAA2 loci; KO/knockdown with in vitro and xenograft/adoptive-transfer functional readouts\",\n      \"pmids\": [\"32788346\", \"32532957\", \"35055045\", \"38491910\", \"37962640\", \"40122823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether neuronal-survival mechanisms operate identically in tumor cells not established\", \"Cross-talk among the multiple disease pathways not integrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How POU4F1 selects among activation, repression, and apoptosis-modulating modes at individual loci—and how a single homeodomain residue and partner identity dictate output—remains mechanistically unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of Brn-3a–DNA–cofactor complexes\", \"Determinants of in vivo site selection beyond conservation and histone state undefined\", \"Unifying logic linking developmental and disease target programs unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 5, 6, 7, 26, 32, 39, 41]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 4, 7, 17, 21, 26, 32, 41]},\n      {\"term_id\": \"GO:0140297\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [9, 21, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 7, 26, 32]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 10, 30, 31, 33, 38]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [9, 16, 20, 21, 29]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [16, 39]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [35, 36, 39, 40, 43]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"POU4F2\", \"TP53\", \"TP73\", \"HIPK2\", \"ISL1\", \"ESR1\", \"EWSR1\", \"RUNX3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}